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ABSTRACT 
 
The six transmembrane epithelial antigen of the prostate 1 (STEAP1) gene was firstly 
identified as over-expressed in prostate cancer, but since then, several studies have 
shown that STEAP1 is also over-expressed in several types of tumors. As STEAP1 
expression is almost absent in normal tissues, it has been pointed STEAP1 as a potential 
biomarker and immunotherapeutic target for cancer. However, the clinical significance of 
STEAP1 expression in prostate cells remains to be clarified.  
At the moment, very little is known about the regulation of STEAP1 in prostate cells, and 
the mechanisms underlying the over-expression of STEAP1 in prostate cancer remain 
unknown. In addition, another STEAP1-related gene is encoded by human genome, 
referred to STEAP1B gene. This gene originates two different transcripts, STEAP1B1 and 
STEAP1B2, probably resulting from alternative splicing. However, no studies are found in 
the literature reporting the characterization of STEAP1B expression in prostate cells. 
Therefore, the main aims of this study was to analyze the STEAP1, STEAP1B1 and 
STEAP1B2 mRNA and STEAP1 protein expression in neoplastic and non-neoplastic 
prostate cell lines by real-time PCR and Western blot, respectively; and to evaluate if 
epigenetic mechanism is involved in regulation of STEAP1 gene expression by bisulfite 
sequencing PCR. In order to evaluate the clinical significance of STEAP1 expression in 
prostate cancer, tissue microarrays were constructed and STEAP1 immunoreactivity was 
determined by immunohistochemical method. A score scale for STEAP1 immunoreactivity 
was established in order to establish associations between STEAP1 immunoreactivity and 
histologic diagnosis or the clinic-pathological data of patients. 
Our results show that STEAP1 is highly expressed in LNCaP and PC3 neoplastic cells 
when compared to PNT1A and PNT2 non-neoplastic cells. On the other hand, STEAP1B1 
and STEAP1B2 showed a slight expression in prostate cell lines. Regarding the 
methylation rate of STEAP1 gene promoter region, no significant differences were found 
between neoplastic (LNCaP) and non-neoplastic (PNT1A and PNT2) prostate cells, 
suggesting that STEAP1 over-expression in LNCaP cells should not be explained by 
hypomethylation at promoter region of STEAP1 gene. However, due to amplification of 
STEAP1 and STEAP1B gene using some sets of primers, these results should be 
confirmed through another strategy. 
By immunohistochemistry technique, it was found that STEAP1 is expressed in cell 
membrane and cytoplasm of epithelial cells, and it is also visible a weaker staining in 
 XI 
 
stromal cells. Our results show that STEAP1 is over-expressed in prostate cancer and 
PIN lesions when compared to adjacent normal tissue or benign prostate hyperplasia, 
suggesting that STEAP1 gene may become over-expressed even before cancer 
development. Finally, it was found that there is a relationship between the STEAP1 
immunoreactivity and Gleason score, but not with other clinic-pathologic data such as 
age, total-PSA, free-PSA, TNM and bone metastasis.  
In summary, we conclude that STEAP1 is over-expressed in neoplastic cell lines when 
compared to non-neoplastic prostate cells, but its over-expression doesn’t seem to involve 
epigenetic mechanisms. STEAP1 is over-expressed in human prostate cancer cases and 
PIN lesions, and its immunoreactivity correlates positively with Gleason score. However, 
more studies are required to clarify the clinical significance of STEAP1 expression in 
prostate cancer. 
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RESUMO 
 
O gene six transmembrane epithelial antigen of the prostate 1 (STEAP1) foi inicialmente 
identificado como um gene sobre-expresso no cancro da próstata. Desde então, vários 
estudos têm mostrado que o STEAP1 é também sobre-expresso em vários outros tipos 
de tumores. Como a expressão do STEAP1 está praticamente ausente em tecidos 
normais, tem sido apontado como um potencial biomarcador e alvo imunoterapêutico 
para o cancro. Contudo, o significado clínico da expressão do STEAP1 nas células da 
próstata continua por clarificar. 
Neste momento, muito pouco é conhecido sobre a regulação do STEAP1 em células da 
próstata, e os mecanismos que conduzem à sobre-expressão do STEAP1 no cancro da 
próstata continuam por ser identificados. Para além disto, um outro gene relacionado com 
o STEAP1 é codificado pelo genoma humano, designado por STEAP1B. Este gene 
origina dois transcritos diferentes, o STEAP1B1 e o STEAP1B2, provavelmente 
resultantes de splicing alternativo. Contudo, não são encontrados estudos na literatura 
descrevendo a caracterização da expressão do STEAP1B em células da próstata. 
Assim sendo, os principais objetivos do nosso estudo são analisar a expressão do mRNA 
STEAP1, STEAP1B1 e STEAP1B2 e da proteína STEAP1 em linhas celulares 
neoplásicas e não neoplásicas da próstata, através de PCR em tempo real e Western 
blot, respectivamente; e avaliar se mecanismos epigenéticos estão envolvidos na 
regulação da expressão do gene STEAP1 através de PCR de Sequenciação bissulfito. 
Para avaliar o significado clínico da expressão do STEAP1 em carcinoma de próstata, 
microarrays de tecido foram construídos e a imunoreactividade do STEAP1 foi 
determinada pela técnica de imunohistoquímica. Uma escala semi-quantitativa para a 
imunorecatividade do STEAP1 foi estabelecida com o objetivo de estabelecer 
associações entre a imunoreactividade do STEAP1 e o diagnóstico histológico ou os 
dados clinico-patológicos dos doentes.  
Os nossos resultados mostram que o STEAP1 é altamente expresso nas células 
neoplásicas LNCaP e PC3 em relação às não neoplásicas PNT1A e PNT2. Por outro lado 
o STEAP1B1 e STEAP1B2 apresentaram uma reduzida expressão nas linhas celulares 
da próstata. Em relação ao rácio de metilação da região promotora do gene STEAP1, não 
foram encontradas diferenças significativas entre as células malignas (LNCaP) e 
benignas (PNT1A e PNT2), sugerindo que a sobre-expressão do STEAP1 nas células 
LNCaP não parece ser explicada pela hipometilação da região promotora do gene 
STEAP1. Contudo, devido à amplificação dos genes STEAP1 e STEAP1B usando alguns 
 XIII 
 
dos pares de primers, estes resultados precisam de ser confirmados usando uma outra 
estratégia. 
Por imunohistoquímica verificou-se uma marcação positiva para o STEAP1 na membrana 
e no citoplasma das células epiteliais, embora seja visível também uma marcação mais 
fraca nas células do estroma. Os nossos resultados mostram que o STEAP1 é sobre-
expresso no cancro da próstata e em lesões de PIN quando comparados com tecido 
normal adjacente ou hiperplasia benigna da próstata, sugerindo que o gene STEAP1 
pode começar a ser sobre-expresso antes do desenvolvimento do cancro. Por fim, foi 
encontrada uma relação entre a imunoreactividade do STEAP1 e os valores de Gleason, 
mas não com outros dados clinico-patológicos como a idade, PSA total, PSA livre, TNM e 
metástases ósseas.  
Em suma, nós concluímos que o STEAP1 é sobre-expresso em linhas celulares 
neoplásicas da próstata quando comparados com as linhas celulares não neoplásicas, 
mas esta sobre-expressão não parece envolver mecanismos epigenéticos. O STEAP1 é 
sobre-expresso em casos de cancro de próstata humana e lesões de PIN, e a sua 
imunoreactividade correlaciona-se positivamente com o valor de Gleason. Contudo mais 
estudos são necessários para clarificar o significado clínico da expressão do STEAP1 no 
cancro da próstata. 
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INTRODUCTION 
 
1 - Prostate anatomy and physiology 
 
The male reproductive system consists of the testis, a serie of ducts, accessory glands 
and supporting structures. The ducts include the epididymides, ductus deferens and 
urethra. The accessory glands include the seminal vesicles, prostate gland and 
bulbourethral glands. The supporting structures comprise the scrotum and penis (Seeley 
2004) (Figure 1 and Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Sagittal section of the male pelvis showing the male reproductive structures, [adapted 
from (Seeley 2004)]. 
 
The prostate gland consists of glandular and muscular tissue and it has the size and 
shape of a walnut, with about 4 cm long and 2 cm wide. It is dorsal to the symphysis pubis 
at the base of the urinary bladder, where it surrounds the prostatic urethra and ejaculatory 
ducts (Seeley 2004). 
The urethra courses through the prostate to become the membranous urethra at the apex 
of the prostate. In the substance of this gland, the urethra merges with the ejaculatory 
ducts and, at this region, angles forwards (Young 2007). 
So, this gland is composed of a fibrous connective tissue containing distinct smooth 
muscle cells and numerous fibrous partitions. Covering these muscular strata, there is a 
layer of columnar cells that secretes prostatic fluid. A range from 15 to 30 small prostatic 
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ducts open into the prostatic urethra, secreting the seminal and prostate fluids and 
spermatozoa (Seeley 2004). 
 
Figure 2: Frontal view of the testes, epididymis, ducts deferens and glands of male reproductive 
system [adapted from (Seeley 2004)]. 
 
The secretions from prostate, seminal vesicles, bulborurethral glands and urethral mucous 
glands help to neutralize the acidic urethra. Moreover, the secretions of the prostate and 
seminal vesicles also help to neutralize the acidic secretions of the testes. The prostatic 
secretions are also important in the transient coagulation of semen, because they contain 
clotting factors that convert fibrinogen from the seminal vesicles to the fibrin, resulting in 
coagulation. After ejaculation, the coagulated material keeps the semen as a single, sticky 
mass for a few minutes, and then fibrinolysin from the prostate causes the coagulum to 
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dissolve, thereby releasing the sperm cells to make their way up the female reproductive 
tract (Seeley 2004). 
Before ejaculation, the ducts deferens begin to contract rhythmically to boost sperm cells 
and testicular fluid from the epididymis to the prostatic urethra, where they blend with 
seminal and prostatic secretions, which are released as a result of contractions of the 
seminal and prostate glands (Seeley 2004). In figure 3 is shown an image of a normal 
prostate. 
 
 
 
 
 
 
 
 
Figure 3: Normal prostate, gross. This is a transversal (axial) section through a healthy prostate. 
There is a central urethra ( ) at the depth of the cut made to open it anteriorly at autopsy, with the 
left lateral lobe ( ), the right lateral lobe (  ), and the posterior lobe (   ). 
[Adapted from (Klatt 2006)]. 
 
The prostate consists of branched tubulo-acinar glands embedded in a fibromuscular 
stroma. On the other hand, in this gland, there also is a partial capsule enclosing the 
posterior and lateral aspects of the prostate but the anterior and apical surfaces are 
bounded by the anterior fibromuscular stroma, which consists, as the name implies, only 
of collagenous stroma and muscle fibers (Young 2007). 
In the past, the prostate was considered to have a huge number of ill-defined lobes. 
However, this terminology has been replaced by the concept of prostate zones. Thus, this 
gland is now described as consisting of four zones of unequal size (Young 2007) (Figure 4 
and Figure 5): 
 The transition zone surrounds the proximal prostatic urethra and comprises about 
5% of the glandular tissue.  
 The central zone (20%) encloses the ejaculatory ducts.  
 The peripheral zone makes up the bulk of the gland (approximately 70%).  
 The anterior fibromuscular stroma contains no glandular tissue and is situated 
anteriorly. 
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Figure 4: Prostate gland H&E x 5, [adapted from (Young 2007)]. The urethral (U) is localized 
centrally and surrounded by a fibrous stroma (St). The ejaculatory ducts (ED) are also found in this 
central stroma as they course towards their junction with the prostatic urethra. The zones of the 
prostate are not clearly demarcated from each other anatomically. Partial fibrous septa (Sp) 
separate the gland into lobules. The transition zone (TZ) surrounds the first part of the prostatic 
urethra. The central zone (CZ) is posterior to the transition zone and encircles the ejaculatory 
ducts. The peripheral zone (PZ) makes up the main bulk of the prostate. The ducts of the 
peripheral zone glands empty into the postero-lateral recesses of the urethra on either side of the 
verumontanum (urethral crest, C). Most cases of carcinoma of the prostate arise in the 
peripheral zone while the transition zone incorporates almost all cases of BPH. At this case, the 
anterior fibromuscular stroma appears continuous with the capsule and its content of muscle fibers 
cannot be discerned. 
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Figure 5: A – Human prostate H&E x 30. B – Human prostate H&E x 50 [adapted from (Young 
2007)].  
 
In figure 5A, it is possible to see that the branching nature of the prostatic gland (G) is 
more apparent. The prostate is irregularly shaped with the epithelium forming folds, which 
allow for expansion of the glands by secretions. This fact gives the epithelium a papillary 
appearance. The secretory product of the prostate, which makes up about half of the 
seminal fluid volume, is thin and milky, rich in citric acid and hydrolytic enzymes, 
especially fibrinolysin, which liquefies the coagulated semen after deposition within the 
female genital tract. Lamellated glycoprotein masses called corpora amylacea (CA) are a 
feature of aging, becoming progressively calcified to form prostatic concretions. The 
stroma of the prostate consists of dense collagen, fibroblasts and haphazardly arranged 
smooth muscle fibers which, like those of the seminal vesicles and the rest of the tract, 
are innervated by the sympathetic nervous system that stimulates powerful contractions 
during ejaculation. Towards the apex of the gland the anterior fibromuscular stroma also 
contains skeletal muscular fibers (Young 2007). 
In figure 5B, the epithelium of the prostate gland is composed by a double layer of cells. 
The luminal layer is composed of columnar secretory cells with basal nuclei. Between the 
secretory cells and the basement membrane, there is a layer of flattened basal cells, 
which probably act as reservoir of cells that replace the dead ones. The basal cell layer is 
often incomplete and may be hard to stain with H&E in sections. However, these cells 
produce a type of high molecular weight-keratin that is not found in the secretory cells 
(Young 2007). 
 
A B 
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Age-related changes have been detected in the prostate gland after 40 years old. By 60 
years old, there is a clear decrease in blood flow, an increased thickness in the epithelial 
cell lining of the prostate gland, and a decrease in functional smooth muscular cells in the 
wall of the prostate. Although the alterations in this gland do not decrease fertility, there is 
a substantial increase in the incidence of benign prostatic hyperplasia (BPH) that can 
create difficulty in urination because it compresses the prostatic urethra (Seeley 2004).  
 
2 - Prostate pathology 
 
Nowadays, there are three pathologic processes that affect the prostate gland with 
emphasis to being discussed: inflammation, BPH and tumors. BPH is the most common 
alteration in prostate and it can be considered as a "normal" process of aging. Prostatic 
carcinoma is also an extremely frequent lesion in man and, therefore, it needs to be 
carefully considered. On the other hand, the clinical significant of inflammatory process is 
reduced and can be easily treated (Kumar 2005).  
 
2.1 - Benign Prostatic Hyperplasia 
BPH is an extremely common disorder in men over 50 years old (Foster 2000; Ramsey 
2000). The etiology of BPH is not completely understood, but it seems to be multifactorial 
and endocrine controlled. BPH consists of two components: static (related to absolute size 
of the prostate gland) and dynamic (associated to prostate smooth muscle contractions), 
that clinically may result in lower urinary tract symptoms of BPH (urinary frequency, 
urgency, sensation of incomplete emptying, weak stream and straining to initiate urination) 
(Facio 2010). 
Histological studies of BPH can be seen in approximately 20% of men with 40 years old, 
increasing to 70% by age 60 and to 90% by age 70. Only 50% of those who have 
microscopic evidence of nodular hyperplasia have clinically detectable enlargement of the 
prostate, and of these individuals, only 50% develop clinical symptoms (Kumar 2005). 
There are some evidences that associate this prostatic enlargement with the action of 
androgens. For example, prepubertal castration prevents the development of nodular 
hyperplasia. 5α-dihydrotestosterone (DHT), a metabolite of testosterone, is the ultimate 
mediator of prostatic growth. It is synthesized in this gland by circulating testosterone by 
the action of the enzyme 5α-reductase type 2. This enzyme is mainly localized in the 
stromal cells; hence, these cells are the main site for the synthesis of DHT (Wong 2000). 
Once synthesized, DHT can act in an autocrine signaling on the stromal cells or in 
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paracrine signaling by diffusing into nearby epithelial cells. In both cases DHT binds to 
nuclear androgen receptor (AR), which acts as a transcription factor regulating the 
expression of several growth factors that are mitogenic to the epithelial and stromal cells 
(Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Simplified scheme of pathogenesis of nodular prostatic hyperplasia – Role of stromal 
cells to generate DHT, [adapted from (Kumar 2005)]. 
 
DHT is 10 times more potent than testosterone because it has greater affinity for the AR. 
While DHT appears to be the major trophic factor mediating prostatic hyperplasia, 
estrogens also appear to play an important role, perhaps by rendering cells more 
susceptible to the action of DHT (Wong 2000). 
The role of DHT in the developing of BPH is supported by clinical observations in which 
an inhibitor of 5α-reductase is given to man with this condition. Therapy with 5α-reductase 
inhibitor reduces the DHT content of the prostate, and consequently, there is a decrease 
in prostatic volume and urinary obstruction. However, not all patients benefit from 
androgen-depriving therapy, suggesting that prostatic hyperplasia may be etiologically 
heterogeneous, and in some cases, other factors besides androgens may be involved 
(McConnell 2003). 
Some studies have demonstrated that BPH are originated almost exclusively in the 
transition zone of prostate gland. Fairly discrete nodules in the periurethral region of the 
prostate are formed, and when sufficiently large, compress and narrow the urethral canal 
to cause partial or complete obstruction of the urethra. The first nodules are composed 
almost entirely of stromal cells; later, predominantly epithelial nodules arise (Kumar 2005). 
On cross-section of the affected prostate, there are nodules that can vary in color and 
consistency. In nodules with primarily glandular proliferation, the tissue is yellow-pink with 
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a soft consistency and a milky white prostatic fluid flows from these structures. In those 
primarily due to fibromuscular involvement, each nodule is pale gray, tough, does not 
exude fluid, and is less clearly demarcated from the surrounding prostatic capsule (Kumar 
2005) (Figure 7). 
 
 
 
 
 
 
 
Figure 7: Gross appearance of prostatic hyperplasia, which is most pronounced in the lateral lobes 
[adapted from (Klatt 2006)]. 
 
Microscopically, the main feature of BPH is the presence of nodules due to glandular 
proliferation and fibrous or muscular proliferation of the stroma. The proportion of these 
elements varies from nodule to other, ranging from only stromal fibromuscular nodules to 
fibroepithelial nodules with a glandular predominance. Glandular proliferation takes the 
form of aggregations of small to large of cystically dilated glands, lined by two layers, an 
inner columnar and an outer cuboidal or flattened epithelium, based on an intact 
basement membrane (Figure 8). Two histologic changes associated with BPH are found: 
(1) foci of squamous metaplasia and (2) small areas of infarction. The former tend to 
occur in the margins of the foci of infarction as nests of metaplastic reactive squamous 
cells that can be confused with adenocarcinoma of the prostate or urothelial carcinoma 
involving the prostate (Kumar 2005). 
 
Figure 8: Prostatic hyperplasia, microscopic. Prostatic hyperplasia can involve glands and stroma, 
although the former are usually more prominent. A large hyperplastic nodule with numerous glands 
is present here. There is still stroma between the glands. The glands are larger than normal, with 
more complex infoldings, but still lined by a double layer of uniform columnar cells and basal 
cuboidal cells that show no atypia. The transitional zone often enables an initial increase in these 
hyperplastic nodules, although the bulk of prostatic enlargement often comes later from 
pronounced nodular growth in the peripheral zone [adapted from (Klatt 2006)]. 
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2.2 - Prostate Cancer 
Prostate cancer is one of the most commonly diagnosed tumors and the second leading 
cause of cancer-related death in European and American men, with approximately 220 
000 new cases of prostate cancer and 30 000 deaths estimated to arise in the US alone in 
2010 (Andriole 2009; Schröder 2009). Concerning Portugal, the last statistics available 
revealed PCa as the most incident neoplasia in men, with 5140 cases in 2008, however 
being the third most lethal cancer (Ferlay 2010). 
There is a large discrepancy between the incidence of the disease and mortality rate. The 
increase of incidence rate can be ascribed to the combination of an aging male population 
and the use of early testing, based on more sophisticated measurement of prostate 
specific antigen (PSA) serum levels. Besides PSA levels in plasma, it has been identified 
novel serum markers such as prostate cancer gene 3 (PCA3) (Hessels 2003).  
Prostate cancer is a disease with a long natural history, with progression commonly 
related to stage and grade of tumor and lack of differentiation (Selley 1997). Several 
reports have described that more than 65% of all prostate cancers are diagnosed in men 
over 65 years old (Madu 2010). Compared with the White population, the incidence of 
prostate cancer is approximately 60% higher in Black men, while native Japanese and 
Chinese population have a low risk of incidence and mortality (Stanford 1999). African-
American men generally are diagnosed with more advanced stages of prostate cancer 
and at an earlier age. Besides to genetics characteristics, social and environmental 
factors (especially diet and lifestyle) may act as the determining factors, which may 
explain why some individuals have higher risk for developing prostate cancer than are 
others (Madu 2010).   
Prostate adenocarcinoma typically proceeds through a series of defined stages, from 
prostatic intraepithelial neoplasia (PIN), to invasive and metastatic cancer (Tomuleasa 
2010).  
The niche is a cell environment that provides critical signals to maintain stem cells and to 
support their undifferentiated phenotype of progenitor cells. These relevant signals include 
the Hedgehog, Wnt or Notch pathways, which all of them are important in early 
ontogenesis and cell differentiation and proliferation control. In cancer, the cell-cell and 
cell-matrix interactions are overlaid on top of other features of tumor physiopathology 
microenvironment, including the presence of hypoxia, low pH and nutrient deprivation. 
Fluctuations of these parameters have profound effects on the activity of cancer stem 
cells and their potential niche (Tomuleasa 2010). 
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Hypoxia is an important characteristic of the niche because it is intrinsically linked to the 
formation of neovasculature and the regulation of the production of proangiogenic factors. 
It is well characterized that several genes are expressed in hypoxic environment, and the 
most of these genes are controlled by hypoxia-inducible factor-1 (HIF-1) (Hill 2009). The 
gene expression may be altered toward an immature phenotype, under hypoxic conditions 
(3 - 5% O2 ), promoting de-differentiation of prostate tumor cells into more “stem-like” ones 
(Das B 2008).  
The hypoxic cells express higher levels of the embryonic stem-ness gene octamer-binding 
transcription factor 4 (OCT-4) due to the interactions between HIF-transcription factors 
(HIF-1α and HIF-2α). OCT-4 is a direct target of HIF-2α, and its induction could contribute 
to the formation and maintenance of cancer stem cells (KoshIji 2004). It should also be 
pointed out that the Myc and OCT-4 oncogenes were two of the four genes that are 
shown to be able of inducing fibroblasts to revert to a stem cell phenotype (Maherali 
2007).  
A number of potentially carcinogenic viruses have been detected in human prostatic 
tissues, such as the oncogenic human papovavirus BK or the human gammaretrovirus 
Xenotrophic MuLV-related virus (XMRV) in premalignant lesions (Urisman 2006; Das D 
2008). These studies have improved the hypothesis of prostate oncogenesis, where PIN 
is preceded by an inflammatory atrophy with prostatic epithelial cells showing an 
increased Ki-67- marked proliferation (Tomuleasa 2010) (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: A model for prostate oncogenesis. The normal epithelium (under oxidative stress, Wnt 
down-regulation or human gammaretrovirus XMRV infection) have an increased proliferative 
potential and eventually lead to the appearance of the PIN. The high proliferative potential and 
telomerase activation determine the evolution from PIN to invasive, metastatic and treatment-
resistant carcinoma [adapted from (Tomuleasa 2010)]. 
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In approximately 70% of the cases, prostate carcinoma arises in the peripheral zone of 
the gland, normally in a posterior location, usually rendering it palpable on rectal 
examination (Figure 10) (Byar 1972). 
Characteristically, on cross-section of the prostate, the neoplastic tissue is gritty and firm, 
but when it embedded within the prostatic substance, it may be extremely difficult to 
visualize and be more readily apparent on palpation. Proliferation of prostate cancer cells 
occurs by direct local invasion and through the bloodstream and lymph. Local extension 
most commonly involves the seminal vesicles and the base of the urinary bladder, which 
may result in urethral obstruction (Potter 2000). Hematogenous spread of cancer occurs 
chiefly to the bones, but some lesions spread widely to viscera (Saitoh 1984). 
 
 
 
 
 
 
 
 
Figure 10: Adenocarcinoma, gross. This axial section reveals a single prominent nodule (*) that 
proved to be adenocarcinoma. Such a nodule may be palpable by digital rectal examination or may 
be detected on ultrasound. Some small dark glandular concretions are also seen in the adjacent 
normal prostate. This prostate is not significantly enlarged, and no nodules are present [adapted 
from (Klatt 2006)]. 
 
Histologically, the most lesions are adenocarcinomas that produce well-defined, readily 
demonstrable gland patterns (Epstein 1995; Epstein 2002). The neoplastic glands are 
typically smaller than benign ones and they are lined by a single uniform cuboidal layer or 
low columnar epithelium. In contrast to benign glands, prostate cancer glands are more 
crowded, characteristically lacking branching and papillary infolding (Figure 11). The outer 
basal layer of cells, typical of normal and hyperplastic glands, are absent in prostate 
cancer. The cytoplasm of the tumor cells ranges from pale to clear, as seen in benign 
glands, to a distinctive amphophilic appearance. Nuclei are large and often contain one or 
more large nucleoli (Figure 12). There is some variation in nuclear size and shape, but in 
general, pleomorphism is not marked. Mitotic figures are extremely uncommon (Rubin 
2002). 
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Figure 11: Adenocarcinoma, microscopic (a). It is possible to observe that the glands of the 
carcinoma are small, irregular, and crowded, with no intervening stroma [adapted from (Klatt 
2006)]. 
 
Figure 12: Adenocarcinoma, microscopic (b). Prominent nucleoli ( ) are a histological feature of 
prostatic adenocarcinoma [adapted from (Klatt 2006)]. 
 
PIN, firstly described in 1969 (McNeal 1969), is a neoplastic proliferation of prostatic 
epithelial cells that is confined to pre-existing prostatic ducts or acini (glands). PIN was 
initially termed intraductal dysplasia by McNeal and Bostwick in 1986. In recent years, 
many studies have shown that high-grade PIN is the major precursor of prostate cancer 
(McNeal 1986). 
The population incidence of high-grade PIN and prostate adenocarcinoma seem to be 
parallel. Previous autopsy studies revealed that high-grade PIN had a low prevalence in 
men during their third decade of life (7% in African Americans vs. 8% in Caucasians) and 
had an increase with aging (91% in African Americans vs. 67% in Caucasians) (Sakr 
1996). 
Preferentially, high-grade PIN and carcinoma involve the peripheral zone of the prostate 
(Bostwick 1996; Häggman 1997), and lately many biomarkers and molecular changes, 
such as TMPRSS2-ERG gene fusion, have been described in both entities (Cerveira 
2006; Perner 2007). The TMPRSS2-ERG gene fusion has been found in 30 to 79% of 
prostate cancer (Tomlins 2005). In some studies, TMPRSS2-ERG gene fusion is 
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associated with severe disease (Perner 2006; Attard 2008), but not in others (Gopalan 
2009). Additionally, up-regulation of the mammalian target of rapamycin (mTOR) pathway 
promotes prostate cancer. The expression of 14-3-3 sigma protein, which regulates the 
mTOR pathway, increase progressively from high-grade PIN through Gleason score 6, 
Gleason score 7, and high-grade prostate cancer (Evren 2011). 
The replication error (RER+) phenotype leads to the inactivation of many tumor 
suppressor genes. In one study, the RER+ phenotype was found in 42% of prostate 
tumors, 16% of PIN lesions and 4% of noncancerous prostate tissues. In this study was 
also found microsatellite instability in 12%, 35%, and 53% of normal, PIN, and cancerous 
tissues, respectively (Miet 1999). 
Fatty acid synthetase (FAS) expression, which is thought to be an early event in malignant 
transformation, has been shown to be over-expressed in high-grade PIN and prostate 
cancer, but no FAS expression was observed in normal tissue (Swinnen 2002). Similarly, 
p53 mutations were detected in 14% of PIN and 25% of prostate cancer lesions 
(Yasunaga 1998). Bcl-2, a proto-oncogene that inhibits apoptosis, is expressed in many 
prostate cancers, and it has also been reported by Baltaci et al. (Baltaci 2000) to be 
expressed in both low-grade PIN and high-grade PIN. In high-grade PIN have also been 
described abnormalities in chromosomes, chromatin structure, and deoxyribonucleic acid 
(DNA) processing enzymes. More than half of high-grade PIN lesions may have 
chromosomal anomalies, including gains of chromosomes (decreasing order of frequency) 
8, 10, 7, 12, and Y (Emmert-Buck 1995; Qian 1995). One study discovered the loss of 
heterozygosity on chromosome 8p12-21 in 63% of PIN lesions in patients with prostate 
tumor (Emmert-Buck 1995). Telomerase, which can contribute to cancer cell 
immortalization, is active in some high-grade PIN foci (Koeneman 1998). DNA 
topoisomerase II-alpha staining by immunohistochemistry is intermediate between benign 
tissue and prostate cancer (Willman 2000). High-grade PIN also displays epigenetic 
changes, including hypermethylation of the several genes, such as glutathione S-
transferase 1 (GSTP1) (Brooks 1998). 
High-grade PIN is characterized by a proliferation of secretory cells with significant 
cytologic atypia within the prostate glands and acini. These secretory cells are enlarged 
with an increased nuclear/cytoplasmic ratio and prominent nucleoli. The cytoplasm of the 
high-grade PIN cells tends to be staining positively for α-methylacyl-CoA. Most of these 
features are shared by invasive prostate cancer (Bostwick 1987; Bostwick 2004; Montironi 
2007). However, in contrast to prostatic adenocarcinoma in which the basal cells are 
absent, in high-grade PIN the basal cell layer is retained although and it is frequently 
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discontinuous on hematoxylin and eosin stain (Bostwick 1987) (Figure 13). Four main 
architectural patterns of high-grade PIN have previously been described (tufting, 
micropapillary, cribriform, and flat), but these are thought to not vary clinically, and 
differentiation seems to have only diagnostic value (Bostwick 1993; Montironi 2007). 
 
Figure 13: Prostatic intraepithelial neoplasia, microscopic. PIN is a precancerous cellular 
proliferation and it is found in a single acinous or small group of prostatic acini. A normal prostatic 
gland ( ) is seen on the left for comparison, with the acini showing PIN (*) on the right. The PIN 
can be low grade or high grade (as seen here). The finding of PIN suggests that prostatic 
adenocarcinoma may also be present, and an adenocarcinoma accompanies high-grade PIN about 
half the time [adapted from (Klatt 2006)]. 
 
2.2.1 - Risk factors 
Usually, prostate tumor is a disease of men over 50 years old, but in men who are at 
increased risk, the recommendations are beginning to start the screening for prostate 
cancer near of 40 years old to detect uncommon cases of this type of cancer before they 
become incurable (Boyle 2003; Kumar 2005). 
Some risk factors, such as age, race, family history, hormone levels and environmental 
influences, are supposed to play important roles in prostate cancer (Yip 1999; Boyle 2003; 
Grönberg 2003; Nelson 2003).  
A number of diet factors appear to be linked to prostate cancer, particularly fat and fiber 
intake. It has been found that prostate cancer incidence is highly correlated with total fat 
intake, particularly animal rather than vegetable fat (Jones 1993; Marchand 1994). The 
evidence about other diet factors is contradictory, being suggested that soya intake as a 
potential protective factor (Messina 1994), and deficiency in vitamin A may lead to 
increase risk of prostate cancer (Pienta 1993). 
It is accepted that there is a little variation in the prevalence of microscopic data of 
prostate tumors around the world, but there are considerable differences in the rates of 
progression to clinically evidence disease. This fact is further shown by migrants moving 
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to higher risk areas acquiring the local incidence rate (Pienta 1993; Haas 1994). Black 
men have a higher risk of prostate cancer than white men. They are more susceptible to 
develop prostate cancer at an earlier age and to have aggressive tumors that grow 
quickly. The exact reasons for these differences are not known and may involve 
socioeconomic and environmental factors. Hispanic men have a lower risk of developing 
prostate cancer and dying from the disease than white men. Prostate cancer occurs most 
often in North America and northern Europe. It also appears that prostate cancer is 
increasing among Asian people living in urbanized environments, such as Hong Kong, 
Singapore, and North American and European cities, particularly among those who have 
a more western lifestyle (Cancer.Net 2012).  
As with BPH, it is believed that androgens have a fundamental role in prostate cancer 
progression. Neoplastic epithelial cells, similar to their normal counterparts, express AR. It 
seems that the role of hormones in this malignancy is essentially tolerant because 
androgens are required for the maintenance of the prostatic epithelium. AR gene 
mutations have been mentioned in only a minority of prostate cancers. However, AR gene 
amplification may also influence androgen-sensitivity of prostatic epithelium. The AR gene 
is polymorphic, with individuals having variable lengths of CAG repeats. Some studies 
have shown that prostate cells with short CAG repeats have an increased sensitivity to 
androgens (Kumar 2005). 
A number of studies have established that genetic factors are involved in some cases of 
prostate tumor. Some authors claim that these are of two types: hereditary prostate 
cancer which is distinguished by early age at onset and autosomal dominant inheritance 
within families; and familial prostate cancer in which members of the same family have the 
disease. Hereditary prostate cancer results from a gene and confers a greatly increased 
susceptibility to the disease. It may account for a substantial amount of early onset 
disease, and overall about 9% of this type of tumor (Bova 1993). Family history of prostate 
cancer has been identified in many studies as a obvious risk factor, accounting with 
approximately 10% of all the cases (Dillman 1994; Ellis 1994; Narod 1995). It has been 
suggested that familiar prostate cancer may be more hostile than that found in the general 
population, because it tends to occur at early ages and accounts for a substantial fraction 
of the disease in younger men (Bova 1993; Li 1993). 
The development of this cancer, in approximately 10% of white American men, has been 
linked to it germ line inheritance susceptibility genes. In one third of these familiar cases, a 
susceptibility gene has been mapped to chromosome 1q24-25. Putative cancer-
suppressor genes that are lost early in prostate carcinogenesis have been localized to 
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chromosomes 8p, 10q, 13q, and 16q. In many cases, the identity of the relevant genes at 
these loci is unknown. p53 mutations in primary prostate cancer are relatively low and 
they are more frequently detected in metastatic disease, suggesting that p53 mutations 
are late events in prostate carcinogenesis (Jussi 2001; Rhodes 2003). Other tumor-
suppressor genes that are thought to play a role in this disease include phosphatase and 
tension homolog (PTEN). Prostate cancers also show a relatively frequent loss of E-
cadherin and CD44 (DeMarzo 2003; Rhodes 2003). In this kind of illness, one of the most 
common genetic alterations is the hypermethylation of GSTP1 gene promoter. More than 
90% of prostate cancers show hypermethylation of this gene, which turn off its expression 
(Kumar 2005). 
 
2.2.2 - Grading and Staging 
Among the various grading systems described, the Gleason system is the best known. 
According to this system, prostate cancers are stratified into five grades on the basis of 
glandular patterns and differentiation degree as observed under low magnification. Grade 
1 represents the well-differentiated tumors, in which the neoplastic glands are uniform with 
round appearance and are packed into well-circumscribed nodules. By contrast, grade 5 
tumors show no glandular differentiation, and the tumor cells infiltrate the stroma in the 
form of cords, sheets, and nests (Figure 14). The other grades fall in between (Gleason 
1974; McNeal 1990; Epstein 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Gleason grades 1 to 5, [adapted from (Humphrey 2008)]. 
 
Nowadays, it is believed that most tumors contain more than one pattern, in which case 
one assigns a primary grade to the dominant pattern and a secondary grade to the 
subdominant pattern. The two numeric grades are then added to obtain a combined 
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Gleason grade or score. Thus, for example, a tumor with a dominant grade 3 and a 
secondary grade 4 would achieve a Gleason score of 7 (Gleason 1974; McNeal 1990; 
Epstein 2001). 
There is consensus that a Gleason score of 1+1=2 is a ranking that should not be 
diagnosed regardless of the type of specimen, with extremely rare exception. Most cases 
in which were diagnosed as Gleason score 1+1=2 would today be referred to as adenosis 
(atypical adenomatous hyperplasia) (Epstein 2011). 
However, there are several reasons why the Gleason score 2-4 should not be assigned to 
cancer on needle biopsy: poor reproducibility even amongst experts; poor correlation with 
prostatectomy grade with almost all cases showing higher grade at resection; a diagnosis 
of Gleason score 3-4 may misguide clinicians and patients into believing that they had has 
an indolent tumor (Steinberg 1997; Epstein 2000). Most of the lesions that appear to be 
very low grade on needle biopsies are diagnosed by urological pathologists as Gleason 
score 2+3=5 or 3+2=5 (Epstein 2011). 
Gleason pattern 3 cancer consists of variably sized individual glands. A further area of 
divergence from the original Gleason system is the controversial area of cribriform 
Gleason pattern 3. Within Gleason's original illustrations of his cribriform pattern 3, he 
depicted large cribriform glands, which the consensus panel would uniformly diagnose as 
cribriform pattern 4. The criteria used to diagnosed cribriform pattern 3 were rounded 
shape, well circumscribed glands of the same size of normal glands. Conceptually, one 
would except the change in grade from pattern 3 to pattern 4 to be reflected in a distinct 
architectural paradigm shift where cribriform as opposed to individual glands are formed, 
rather the merely a subjective continuum of differences, in size, shape and contour of 
cribriform glands (Epstein 2011). 
Ill-defined glands, with poorly formed glandular lumina also demand the diagnosed of 
Gleason pattern 4. Only a cluster of such glands, where a tangential section of Gleason 
pattern 3 glands cannot account for the histology, would be acceptable as Gleason 
pattern 4. Nevertheless, it was noted that in most cases of ill-defined glands with poorly 
formed glandular lumina are accompained by fused glands. Very small, well-formed 
glands are still within the spectrum of Gleason pattern 3. This definition differs from 
Gleason's original description of pattern 4 which only included the hypernephromatoid 
pattern (Gleason 1966). 
The original schematic diagram of Gleason pattern 4 consisted almost entirely of 
cribriform patterns without depicting fused glands or ill-defined glands with poorly formed 
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glandular lumina. Gleason patterns 4 are closely resembling renal cell carcinoma 
(hypernephromatoid pattern) makes up only a very small percentage of Gleason pattern 4 
cases (Epstein 2011). 
Gleason pattern 5 consists of individual or cords of cells and sheets of tumor. Although 
typically one sees comedonecrosis with solid nests, occasionally one can see necrosis 
with cribriform masses that by themselves might be cribriform pattern 4. If there is true 
comedonecrosis, the consensus was that these patterns should be regarded as Gleason 
pattern 5. One must be stringent as to the definition of comedonecrosis, requiring 
intraluminal necrotic cells and/or karyorrhexis, especially in the setting of cribiform glands 
(Figure 15) (Epstein 2011). 
 
 
 
 
 
 
Figure 15: Different Gleason score of adenocarcinomas. A, Low-grade (Gleason score 1 + 1 = 2) 
prostate cancer consisting of back to back, uniformly sized malignant glands. Glands contain 
eosinophilic intraluminal prostatic crystalloids, this feature that is more commonly seen in cancer 
than in benign glands and more frequently seen in lower grade than in higher grade prostate 
cancer. B, Needle prostate biopsy with variably sized, more widely dispersed glands of moderately 
differentiated (Gleason score 3 + 3 = 6) adenocarcinoma. C, Poorly differentiated Gleason score (5 
+ 5 =10) adenocarcinoma composed of sheets of malignant cells, [adapted from (Kumar 2005)]. 
 
Staging of prostatic cancer is important in the choice of the appropriate form of therapy. 
The most common staging system is the TNM system. Stage T1 refers to cancer which is 
found incidentally either on trans-urethral resection done for BPH symptoms (T1a and T1b 
depending on the extent and grade) or on needle biopsy, typically performed for elevated 
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serum PSA levels (stage T1c). Stage T2 is defined as organ-confined cancer. Stage T3a 
and T3b tumors exhibit extraprostatic extension, with and without seminal vesicle 
invasion, respectively. Stage T4 shows direct invasion of contiguous organs. Any spread 
of tumor the lymph nodes, regardless of extent, is eventually associated with a fatal 
outcome, such that the staging system merely records the presence or absence of this 
finding (NO/N1) (Epstein 1994; Matzkin 1994) (Table 1). 
 
Table 1: TNM system for staging the prostate cancer (Sobin 2009). 
Primary tumor Tx Tumor has not evaluated or not evaluable 
 T0 No evidence of tumor 
T1 Tumor clinically not apparent by palpation or ultrasound 
 T1a Incidental finding of tumor in <5% of prostate tissue resected 
T1b Incidental finding of tumor in >5% of prostate tissue resected 
T1c Tumor diagnosed after PSA elevation 
T2 Tumor confined to prostate 
 T2a Tumor involving up to half of one lobe of the prostate 
T2b Tumor involving more than half a lobe of the prostate (not both) 
T2c Tumor involving both lobes of the prostate 
T3 Tumor with extraprostatic extension 
 T3a Extension through the prostate capsule 
T3b Invasion of seminal vesicles 
T4 Tumor fixed or invading adjacent structures (colo vesical, external 
urethral sphincter, rectum, parede pelvic ósteo-muscular) 
Lymph Nodes Nx Regional lymph nodes were not evaluated or not evaluable 
 N0 No evidence of regional lymph node compromise 
N1 Metastasis to regional lymph nodes 
Metastasis Mx Distant metastasis were not evaluated or not evaluable 
 M0 No evidence of distant metastasis 
M1 Distant metastasis 
 M1a Non-regional lymph nodes 
M1b Bone 
M1c Other locations 
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2.2.3 - Genes regulation by Epigenetic Mechanisms 
Epigenetics changes may lead to alteration of gene expression, since they do not involve 
a modification in the DNA sequence or the proteins encoded by their genes (Jones 1999). 
Epigenetic phenomena is mediated by a variety of molecular mechanisms, including 
posttranslational histone modifications, histone variants, adenosine 5’-triphosphate (ATP)-
dependent chromatin remodeling complexes, polycomb/trithorax protein complexes, small 
and other noncoding RNAs such as short interfering RNA (siRNA) and microRNAs 
(miRNAs), and DNA methylation (Tost 2008).  
DNA methylation is highly related with several chromatin modifications. On the other 
hand, enzymes that modify DNA and histones have been shown to interact directly with it 
and they link with local DNA methylation and local chromatin structure (Tost 2009). 
Cancer is possibly the best-studied disease with a strong epigenetic component (Jones 
2002; Laird 2005). In tumors, a global loss of DNA methylation (hypomethylation) of the 
genome is observed (Feinberg 1983) and it has been suggested as an initiator and 
propagator of oncogenesis by inducing chromosome instabilities and transcriptional 
activation of oncogenes and prometastatic genes such as r-ras (Ehrlich 2002). The overall 
decrease in DNA methylation is accompanied by a region and gene-specific increase of 
methylation (hypermethylation) of multiple CpG islands  (Jones 2002; Laird 2005). 
Hypermethylation of CpG islands in the promoter region of the tumor suppressor or 
otherwise cancer related gene is often associated with transcriptional silencing of the 
associated gene. The number of gene-associated promoters that are known to become 
hypermethylated during carcinogenesis is rapidly growing. Genes of numerous pathways 
involved in signal transduction (adenomatosis polyposis coli (APC)), DNA repair (O-6-
methylguanine-DNA methyltransferase (MGMT), mutL homolog 1 (MLH1), and breast 
cancer 1 (BRCA1)), detoxification (GSTP1), cell cycle regulation (p15, p16, and 
retinoblastoma protein (RB)), differentiation (myogenic differention 1 (MYOD1)), 
angiogenesis (thrombospondin 1 (THBS1) and von Hippel-Lindau tumor suppressor 
(VHL)) and apoptosis (Caspases, p14, and death-associated protein kinase (DAPK)) are 
often inappropriately inactivated by DNA methylation. So far no single gene has been 
identified that is always methylated in a certain type of cancer. Both hypo- and 
hypermethylation are found in the same tumor, but the mechanisms that lead to both 
phenomena have not yet been elucidated (Frigola 2006).  
A new dimension has recently been added to epigenetic cancer research with the 
demonstration of long-range gene silencing by epigenetic modifications (Frigola 2006). 
Long-range epigenetic silencing seems to be a prevalent phenomenon during 
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carcinogenesis, as a recent survey identified 28 regions of copy-number-independent 
transcriptional deregulation in bladder cancer that are potentially regulated through 
epigenetic mechanisms (Stransky 2006).  
Although important genetic factors are involved in cancer, such as BRCA1 and p53 
mutations in familial cancers, epigenetic changes occur at higher frequency when 
compared to genetic alterations and may play an important role in early-stage of human 
neoplasia (Goelz 1985; Costello 2000).  
 
2.2.4 – Biomarkers of prostate cancer 
According to the National Cancer Institute, a biomarker is “a biological molecule found in 
blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a 
condition or disease” (Figure 16). A biomarker may be objectively measured and 
evaluated as an indication of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a particular treatment or condition (Atkinson AJJr 2001). 
Biomarkers are extensively used as analytical tools to assess biological parameters for a 
rapid and comprehensive therapeutic analysis. In addition, biomarker measures can 
further the development and evaluation of new therapies (Rolan 1997). 
Biomarkers that represent highly sensitive and specific indicators of disease pathways are 
frequently used as substitutes for outcomes in clinical trials where they can be used to 
predict and evaluate the clinical risk and/or benefit of a treatment, which is the optimal 
objective of all therapeutic interventions (Lagakos 1992).  
 
Figure 16: General classification of biomarkers based on their description, [adapted from (Ludwig 
JA 2005)]. 
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Usually, the cancer biomarkers are classified into three different categories: prognostic, 
predictive, and pharmacodynamic. Prognostic biomarkers predict the natural course of the 
cancer, to distinguish the tumor’s outcome; help to determine whom to treat, how 
aggressively to treat, and which candidates will likely respond to a given drug and the 
most effective dose. Predictive biomarkers evaluate the probable benefit of a particular 
treatment. Pharmacodynamic biomarkers assess the imminent treatment effects of a drug 
on a tumor and can possibly determine the proper dosage in the early stages of clinical 
development of a new anticancer drug (Sawyers 2008). 
 
Among the various proteins used as biomarkers (described in figure 16), which is more 
used in assessing prostate cancer in its early stage, is the PSA. However, the utilization of 
PSA as biomarker has been presented several limitations and others proteins have been 
also pointed as potential biomarkers. Recently, some emphasis has been given to six 
transmembrane epithelial antigen of the prostate 1 (STEAP1), which was identified as 
over-expressed in prostate cancer.  
 
2.2.4.1- PSA 
PSA is a serine protease that has been used extensively in clinical practice since 1988. It 
is the best-known member of the kallikrein family, which is the largest proteases group in 
human genome that is clustered in a 300-kilobase region on chromosome 19q13.4. In 
clinical practice, the levels of PSA in serum have been used extensively for risk 
stratification of prostate cancer. The levels of PSA are also used for monitoring disease 
recurrence after initial treatments and for evaluating response to cancer treatments (Kohli 
2010). 
In serum, PSA is bound primarily by α1-antichymotrypsin (ACT), an endogenous protease 
inhibitor, and also by another similar inhibitor, α2-microglobulin. PSA was initially thought 
to be solely synthesized by epithelial cells of the prostate, and thus, it could be used as a 
biomarker for prostate cancer diagnosis (Chu 1997). However, PSA has also been found 
in a variety of human normal and tumor cell lines, and in several biological fluids 
synthesized by numerous cells (Chu 1997; Polascik 1999; Rao 2008). 
Despite uncertainty regarding the value of routine PSA testing, it has been widely used. 
Furthermore, there are problems with sensitivity and specificity using standard PSA 
testing strategies (Abrahamsson 1997). 
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The sensitivity of PSA for detection of prostate cancer ranges from 63% to 83%. The 
specificity is lower in men with larger prostate glands or those with lower urinary tract 
symptoms (Harris 2001). 
The main advantage of PSA testing is its sensitivity. However, the main disadvantage of 
this test is its low specificity, because some common pathological conditions such as BPH 
and prostatitis can also increase the levels of PSA (Oh 2003). 
In order to overcome the problems associated with sensitivity and specificity, a variety of 
diagnostic parameters and tests have been proposed. However, none of them have been 
proved to be beneficial or superior to current PSA reference ranges. Refinements include 
lowering the cutpoint for defining an abnormal PSA level to below 4.0 ng/mL (e.g.,below 
3.0 ng/mL), age-specific PSA, PSA velocity (PSA-V), volume-adjusted PSA densities, the 
free-to-total PSA ratio (%fPSA), and bound/ complexed PSA (Labrie 1992). 
The PSA-V is the most useful if three or more measurements are obtained over an 
interval of 1 to 3 years (Mettlin 1994). An abnormal PSA-V has been defined if the levels 
of PSA increase more than 0.75 ng/mL per year. Because prostate inflammation 
contributes to PSA elevations, the use of PSA-V change after antibacterial therapy for 
infectious/inflammatory symptoms might help differentiate benign and malignant 
conditions in men with elevated PSA (Stenman 1994). 
PSA circulates in two forms: free and complexed with molecules such as ACT. Men with 
prostate cancer tend to have a lower percentage of their PSA in the free form compared 
with men without prostate cancer (Stenman 1994). The free/total PSA measurements 
might help to differentiate between prostate cancer and normal prostate conditions among 
men with PSA concentrations between 4.0 ng/mL and 10 ng/mL. To be useful, a negative 
value for %fPSA would need to reduce the probability of prostate cancer to a low enough 
level that men would be willing to forego biopsy (Hoffman 2000). PSA complexed with 
ACT, α2-macroglobulin or α1-protease inhibitor as well as human glandular kallekrein-2 
might hold promise when evaluating the need for repeat biopsies in men with a mildly 
elevated PSA and negative initial biopsy (Wilt 2003). 
PSA levels are normally elevated in older men relative to younger one, regardless of the 
absence or presence of cancer. Therefore, a continuous rise in PSA levels over time may 
be more indicative of cancer than moderately increased of PSA (Carter 1992). Higher 
PSA values have also been observed in African American men with newly diagnosed 
prostate tumor when compared with newly diagnosed Caucasian men (Moul 1995). 
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The levels of PSA in serum can independently predict a pathological stage. However, the 
serum PSA level alone may not adequately calculate pathological stage because the 
relationship between pathological stage and serum PSA varies by tumor grade, volume, 
and origin site (Partin 1993; Stamey 1993). Nevertheless, comparative studies have 
demonstrated that PSA and its related testing can increase the detection rate of prostate 
cancer in men with no symptoms (Mettlin 1991; Catalona 1993). It has also been shown 
that the stage distribution of cancers detected through PSA is much more favorable (Madu 
2010). 
 
2.2.4.2 - STEAP1 
The STEAP family of proteins is a relatively new family comprising four members named 
STEAP1 to STEAP4. STEAP1 and STEAP2 are mainly expressed in the prostate, 
whereas the expression of STEAP3 and STEAP4 in human tissue is highest in bone 
marrow, followed by placenta and fetal liver (Ohgami 2006). 
STEAP1 protein is composed by 339 aminoacids with a molecular weight of 36 KDa, and 
it is localized on chromosome 7q21, a region close to the telomeric sequences. STEAP1 
was identified as over-expressed in prostate cancer and in several cancer cell lines of 
various origins, such as pancreas, colon, breast, testicular, cervical, bladder and ovarian 
carcinoma, acute lymphocytic leukemia and Ewing sarcoma. STEAP1 is absent in normal 
human tissues except in prostate and bladder (Hubert 1999). 
 
STEAP1 protein  presents a molecular topology of six transmembrane domains with  
intracellular N- and C- terminals and three extracellular and two intracellular loops  
(Hubert 1999). Its structure prediction and location at cell–cell junctions suggests that 
STEAP1 may act as a channel, or a transport protein in tight or gap junctions, or in cell 
adhesion (Hubert 1999; Kobayashi 2007). In fact, recent data showed that STEAP1 is  
involved in intercellular communication between adjacent cells in culture, and that it 
seems to favor tumor development (Challita-Eid 2007) (Figure 17). 
 
Introduction 
 
25 
 
 
Figure 17: STEAP gene organization, mRNA transcripts and predicted protein structure. Green 
boxes correspond to exons, [Adapted from (Santos 2010)]. 
A detailed in silico analysis allow us to identify another gene related to STEAP1, which is 
known as STEAP1B. This gene is localized on chromosome 7p15.3 and may originate 
two different transcripts, namely STEAP1B1 and STEAP1B2. STEAP1B1 is the longer 
transcript and may encode the longer isoform. STEAP1B2 transcript uses an alternate in-
frame splice site in the 5' coding region and an alternate 3' exon with a distinct 3' coding 
region and 3' UTR, compared to variant 1. STEAP1B1 and STEAP1B2 have a predicted 
molecular weight of 42 KDa  and 30 KDa, respectively. The STEAP1B2  isoform lacks an 
internal segment near the N-terminus and has a shorter and distinct C-terminus, when 
compared to STEAP1B1 isoform (http://www.ncbi.nlm.nih.gov/gene?term=STEAP1B). Of 
our knowledge, no studies have been conducted regarding the expression of STEAP1B in 
human prostate cells. 
At this time, very little is known about the regulation of STEAP1. Previously, our research 
group has demonstrated  that STEAP1 is down-regulated by 17β-estradiol (E2) in MCF-7 
breast cancer cells (Maia 2008). Recently, we also demonstrated that DHT and E2 down-
regulates STEAP1 expression in LNCaP prostate cancer cells (Gomes (in press)). 
However, the molecular mechanisms underlying the over-expression of STEAP1 in 
prostate cancer remain unknown. 
As described previously, cancer presents a strong epigenetic component, which may lead 
to deregulation of gene expression without involve a modification in DNA sequence 
(Jones 2002; Laird 2005).  
Regarding the STEAP gene family, Tamura and Chiba demonstrated that CpG islands in 
STEAP4 promoter region were frequently methylated in DU145, androgen-independent 
prostate cancer cells, and this may down-regulate STEAP4 gene expression (Tamura 
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2009). In silico analysis of the promoter region and first intron of STEAP1 gene, it was 
observed that this region also presents a CpG islands (see Figure A1 in appendix), raising 
the question whether STEAP1 may also be regulated by methylation mechanisms. 
As STEAP1 is highly expressed at cell membrane in several types of tumors but not in 
most vital organs in human, turned STEAP1 into a potential target for antitumor 
immunotherapy (Gomes 2012). In fact, STEAP1 peptide epitopes can be used to 
stimulate cytotoxic T and helper T lymphocytes, which kill STEAP1 expressing tumor cells 
(Alves 2005). In addition, murine STEAP1 (mSTEAP1)-based vaccination was able to 
induce a specific CD8 T-cell response against a newly defined mSTEAP1 epitope that 
prolonged the overall survival rate in tumor-challenged mice very significantly (Garcia-
Hernandez 2007). 
Although several studies have been pointed STEAP1 as a potential biomarker in human 
cancer, especially in prostate and Ewing tumors (Li 2004; Valenti 2008; Grunewald 2011), 
the relationship between STEAP1 expression in prostate cells and clinic-pathological data 
are scarce and more studies are required.  
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AIMS 
 
Considering the incidence and the mortality of prostate cancer and some of the limitations 
of the PSA test as a marker of this disease, we believe that it is important to study novel 
putative biomarkers in prostate cancer. 
Although it is well characterized that STEAP1 is over-expressed in prostate cancer cell 
lines, the mechanisms that conduct its over-expression remains unknown. In addition, no 
studies are found in the literature regarding the characterization of STEAP1B expression 
in prostate cells.  
Several studies have been pointed STEAP1 as a potential biomarker or therapeutic target 
in cancer, but the clinical significance of STEAP1 expression in prostate cancer remains 
poorly understood. In order to better understand the STEAP1 and STEAP1B expression, 
regulation and its clinical significance in prostate cancer, the following aims were 
delineated: 
 
 To analysis the STEAP1, STEAP1B1 and STEAP1B2 messenger ribonucleic acid 
(mRNA) and STEAP1 protein expression in human prostate cell lines; 
 To evaluate whether promoter region of STEAP1 gene has different methylation 
pattern between neoplastic and non-neoplastic prostate cells;  
 To analysis the STEAP1 expression in tissue microarrays (TMAs) of human 
prostate and compare its immunoreactivity with the clinical profile, biochemical, 
and pathological data of patients. 
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MATERIALS AND METHODS 
 
1 – STEAP1 gene and protein expression in prostate cell lines and its 
regulation by epigenetic mechanisms. 
 
1.1 - Cell lines culture 
In this study were used four cell lines of prostate, LNCaP and PC3 (neoplastic cell line: 
LNCaP – Androgen-sensitive and PC3 – androgen independent), PNT1A and PNT2 (non-
neoplastic cell lines) that were purchased from the European Collection of Cell Cultures 
(ECACC, Salisbury, UK). All cell lines were cultured in recommended medium with RPMI 
1640 phenol-red (Invitrogen) in the presence of 10% FBS and 1% penicillin/streptomycin 
(Invitrogen) in a humidified atmosphere at 37ºC containing 5% CO2.  
1.2 - Mycoplasma testing 
In order to ensure that cell lines culture was mycoplasm-free, 100μl of cell culture medium 
was removed to an eppendorf. The medium was incubated at 95ºC for 5 min and then 
was centrifuged for 5 min at 10000rpm.  
Next, PCR reactions were carried out with the purpose to detect mycoplasm 
contamination in culture medium. A mixture was prepared for the first PCR with 8.05μl of 
Miliq water, 2.5μl of 10x buffer ((NH4)2SO4 and MgCl2), 0.75μl of MgCl2 (50 mM), 1μl of 
dNTPs (10mM), 7.5μl of primers mix (10μM) (Table 2), 0.2μl of Taq polymerase 
(Fermentas) (5U/μl) and 5μl of culture medium. The tubes were incubated at 94ºC for 10 
min followed by 35 cycles of 30 sec at 94ºC, 2 min at 55ºC, and 1 min at 72ºC, followed 
by a final elongation for 8 min at 72ºC on a PCR system. Amplified PCR products were 
analyzed on a 2% agarose gel and the results were visualized in an image analyzer 
(UVITEC - Cambridge).   
As the samples were negative in the first PCR, it was prepared a second PCR with 
12.05μl Miliq water; 2.5μl of 10x buffer ((NH4)2SO4 and MgCl2); 0.75μl of MgCl2 (50 mM); 
1μl of dNTPs (10mM); 7.5μl of primers mix (10μM); 0.2μl of Taq polymerase (Fermentas) 
(5U/μl) and 1μl of amplification product of the first PCR. The samples were incubated at 
94ºC for 10 min followed by 30 cycles of 30 sec at 94ºC, 2 min at 55ºC, and 1 min at 
72ºC, followed by a final elongation of 8 min at 72ºC on a PCR system. Amplified products 
were analyzed on a 2% agarose gel. 
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Table 2: Sequences of the specific primers used to mycoplasm test. 
 
 Sequence (5’-3’) Sequence (5’ – 3’) 
1º PCR 
 
MycoF1t 
MycoR1cat 
MycoR1 
MycoR1ac 
MycoR1tt 
MycoF1 
ACA CCA TGG GAG TTG GTA AT 
CCT CAT CGA CTT TCA GAC CCA AGG CAT  
CTT CAT CGA CTT TCA GAC CCA AGG CAT  
 CTT CAT CGA CTT CCA GAC CCA AGG CAT  
 CTT CTT CGA CTT TCA GAC CCA AGG CAT  
 ACA CCA TGG GAG CTG GTA AT  
Nested 
PCR 
 
MycoF2 
MycoF2cc 
MycoF2a 
MycoR2 
MycoR2cc 
MycoR2at 
GTT CTT TGA AAA CTG AAT  
 GCT CTT TCA AAA CTG AT  
ATT CTT TGA AAA CTG AT  
 GCA TCC ACC AAA AAC TCT  
 GCA TCC ACC ACA AAA CTC  
 GCA TCC ACC AAA TAC TCT  
 
 
1.3 - Extraction of total ribonucleic acid (RNA) and cDNA synthesis  
Total RNA was isolated from LNCaP, PNT1A, PNT2 and PC3 cells using Tri reagent 
(Sigma). For this, 500 μl of this reagent was added to cells and 40 μl of a chloroform 
solution. The solution was homogenized by vortex for about 15 seconds and stands at 
room temperature for 15 minutes. Next, samples were centrifuged at 12000 x g for 15 
minutes at 4ºC, in order to promote the separation of the different components in different 
phases: a reddish organic phase consisting of proteins; a white intermediate phase that is 
the DNA; and an upper aqueous phase containing RNA. This aqueous phase was 
removed for into a clean 1.5 ml microcentrifuge tubes and 100 μl of isopropanol solution 
was added to precipitate RNA and remained for about 10 minutes at room temperature. 
Samples were centrifuged at 12000 x g for 10 minutes at 4ºC and the supernatant was 
discarded. Total RNA pellet was washed twice, by adding 200 μl of a solution of 75% 
ethanol, then, was homogenizated in vortex mixing, and centrifuged at 7500 x g for 5 
minutes at 4ºC. Finally, pellets were dried for 5 minutes at room temperature, and 
dissolved in 20 μl of H2O DEPC-treated. 
In order to evaluate the quantity of total RNA, its optical density at 260 nm and 280 nm 
was determined (Pharmacia Biotech, Ultrospec 3000), and the integrity of RNA was 
verified through agarose gel electrophoresis.  
For cDNA synthesis, 1 μg of total RNA was subjected to reverse transcription for PCR, 
according to the manufacturer’s instructions. Briefly, total RNA was denatured for 5 min at 
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65ºC in a 10 μl reaction containing random hexamer primers (100 µM) and DEPC-treated 
water. A mix was prepared for a 10 ul reaction containing reverse transcriptase buffer 
RiboLock™ Rnase Inhibitor (20 u/µl);  dNTPs (10mM) and M-MuLV Reverse 
Transcriptase (20 u/µl). This mixture was added to the previously denatured RNA. 
Reverse transcription was carried out at 37ºC for 60 min and was stopped after 15 min at 
75ºC. 
 
1.4 – Conventional polymerase chain reaction (PCR) and Real-Time PCR 
Conventional PCR was used to evaluate the quality of cDNA samples, which were 
assessed using a GAPDH housekeeping gene. Then, as first approach, the expression of 
STEAP1, STEAP1B1 and STEAP1B2 genes were carried out by PCR, using specific 
primers (Table 3). PCR reactions were performed in a 25 ul reaction volume containing 1 
μl of synthesized cDNA; DreamTaq buffer (KCl, (NH4)2SO4 and MgCl2 20mM); dNTP (10 
mM) (Amersham); MgCl2 (50mM); 50 nM of each primer and 0,125 U DreamTaq
TM 
polymerase (Fermentas). Reaction tubes were kept on ice to prevent non-specific 
amplification and incubated for 5 min at 94ºC, followed by 30 cycles of 30 sec at 94ºC, 30 
sec at 56ºC, and 1 min at 72ºC, and a final elongation step of 5 min at 72ºC on a 
Tprofissional Basic Gradient - PCR system (Biometra). Amplified products were analyzed 
on a 1% agarose gel and the results were visualized in an image analyzer (UVITEC - 
Cambridge).  
Real-time PCR was used to quantify the expression of STEAP1 mRNA levels in 
neoplastic (LNCaP, PC3) and non-neoplastic cells (PNT1A, PNT2). Real time PCR 
reactions were carried out using 1μl of cDNA synthesized, in a 20μl reaction containing 
10μl SYBR Green Supermix (Biorad) and the appropriate concentration of each primer: 
1.2μl STEAP1 primer (300nM) and 1.2ul GAPDH primer (300nM), (Table 3). After an initial 
denaturation at 95ºC during 5 min, cycling conditions (35 cycles) were the following: 95ºC 
for 10 sec, annealing temperature at 60ºC for 30 sec and 72ºC for 10 sec, on an IQ5 
Multicolor Real Time PCR Detection System (Bio-Rad). The amplified PCR fragments 
were checked by melting curves: reactions were heated from 55 to 95ºC with 10 sec holds 
at each temperature (0.05.C/s). Samples were run in triplicate in each real-time PCR 
assay. Fold differences were calculated following the mathematical model proposed by 
Pfaffl using the formula 2 -(ΔΔCt) (Pfaffl 2001). The results presented were obtained by a 
Log2 transformation of real-time PCR data. 
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Table 3: Details of specific primers used for amplication of STEAP1, STEAP1B1 and STEAP1B2.  
 
1.5 - Protein extraction and Western Blot 
Prostate cell lines were lysed in 100μl of Radioimmunoprecipitation assay buffer (RIPA) 
(150mM NaCl, 1% Nonidet-P40 substitute, 0.5% Na-deoxycholate, 0.1% SDS, 50mM Tris, 
1mM EDTA, 1% Protease cocktail and 1mM PMSF). The total proteins (supernatant) were 
recovered after a 12000 x g centrifugation for 20 min at 4ºC. Quantification of total protein 
extracts was assessed using the Bradford method (Biorad Protein Assay). 
Western Blot was carried out to determine the expression of STEAP1 protein in prostate 
cell lines. Firstly, the proteins were denaturated for 5 min at 100ºC and ran on a 
polyacrylamide gel (12.5% resolving gel and 4.7% stacking gel), for 90 min, at 140V. The 
resolving gel was constituted by 4.15ml acrylamide (40%); 3.75ml Tris-HLC 1.875M pH 
8.8; 1.85ml H2O; 0.1ml SDS 10%; 125μl PSA 10% and 15μl TEMED, and the stacking gel 
by 0.875ml acrylamide (40%); 0.625ml; 3,45ml H2O and 1 ml SDS 10%; 125μl PSA 10% 
and 15μl TEMED.  
PVDF membrane was activated in methanol (5 sec.), H2O (5 min) and electrophoresis 
buffer (10mM CAPS in methanol 10%, pH 11) (5 to 15 min). Proteins were electro-
transferred from gel to PVDF membrane in CAPS electrophoresis buffer at 750 mA for 30 
min. Membrane was blocked during 1h, at room temperature, in blocking solution (TBS-T 
5% milk) before incubation overnight with a rabbit polyclonal antibody against human 
STEAP1 (H-105, Santa Cruz Biotechnology, Santa Cruz, USA) diluted 1:300 with TBS-T 
1% milk. After that, membrane was washed three times in washing buffer (TBS-T 0.5% 
milk) for 45 min, and then, incubated with alkaline phosphatase conjugated with the 
secondary antibody (1:20000 dilution) for 1 h at room temperature. The membrane was 
washed again during 45 min, under the same conditions; at last, this membrane was air 
Gene name Oligo name Sequence (5’-3’) 
Amplicon 
size (bp) 
STEAP1 
(NM_012449.2) 
hSTEAP1_980fw 
hSTEAP1_1181rv 
TTCCCTTCTACTGGGCACAA 
202 
GACGTCTTCCCAACCATGTC 
STEAP1B1 
(NM_001164460.1) 
hSTEAP1B_isof1fw 
hSTEAP1B_isof1rv 
CTGGAAGCCTGGTAGCTTTG 
162 
GGCTGGCTGCTGATAAAATG 
STEAP1B2 
(NM_207342.2) 
hSTEAP1B_isof2fw 
hSTEAP1B_isof2rv 
CGATTATTTGCAAACAGCCC 
173 
GGGAAGTTGCTAAAGGGTGA 
GAPDH 
(NM_002046) 
hGAPDH_74fw 
hGAPDH_149rv 
CGC CCG CAG CCG ACA CAT C 
CGC CCA ATA CAA TCC G 
75 
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dried and incubated with 800 μl ECF reagent for 2 – 3 min, and exposed to 
chemiluminescence’s detection in a Molecular Imager FX (Biorad, Hercules, USA). 
The same membranes probed with anti-STEAP1 were incubated with mouse anti α-tubulin 
antibody diluted 1:5,000 (Sigma) and then with goat anti-mouse IgG phosphatase alkaline 
conjugated secondary antibody diluted 1:20,000 (Abcam, Massachusetts,MA). The 
expression levels of STEAP1 and α-tubulin proteins were quantified by densitometry using 
Quantity One software (Biorad, Hercules). The signal of STEAP1 was normalized to the 
corresponding α-tubulin signal. 
 
1.6 - DNA extraction and quantification 
DNA was extracted from LNCaP, PNT1A and PNT2 cells using the Gentra Puregene Cell 
Kit (QIAGEN). The cells were centrifuged for 5 sec at 13400 x g and the supernatant was 
discarded by pipetting. The solution was homogenized by vortex to resuspend the cells in 
the residual supernatant. Next, 300μl of Cell Lysis Solution was added to resuspended 
cells with up and down pipetting. 100μl of Protein Precipitation Solution was added to 
samples and then, they were homogenized and vortexed for 20 sec at a high speed, 
which was followed by further centrifugation for 1 min at 13400 x g. After to add 300μl 
isopropanol into a clean 1.5ml microcentrifuge tubes, the supernatant from the previous 
step was dropped carefully. The tubes were mixed by gently inverting about 50 times. 
Then, the samples were centrifuged for 1 min at 13400 x g and the supernatant was 
discarded. Subsequently, 300μl of 70% ethanol was added to wash the DNA pellet, which 
was centrifuged for 1 min at 13400 x g and so, the supernatant was discarded. After 
drying the DNA at room temperature for 15 min, 50μl DNA Hydration Solution was added 
and homogenized by vortex during 5 sec at medium speed. The tubes were incubated at 
room temperature overnight with gentle shaking.  
To access the quantity of DNA, its optical density at 260 nm and 280 nm was quantified 
(Pharmacia Biotech, Ultrospec 3000), and the integrity of DNA was verified through an 
agarose gel electrophoresis. 
 
1.7 - Bisulfite modification of DNA  
Sodium bisulfite treatment performs a chemical modification in cytosine bases. It is based 
on the different sensitivity of cytosine and 5-methylcytosine to deamination by bisulfite, 
where unmethylated cytosines are converted to uracil and that methylated cytosines 
remain as cytosines. This method is crucial in Epigenetic, because it allows the analysis of 
methylation levels in CpG islands in genomic DNA. Bisulfite modification consists mainly 
in four steps: an initial denaturation to allow a better efficiency of the bisulfite’s action; a 
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sulphonation resulting in the formation of a sulphonated cytosine derivate; a hydrolytic 
deamination step to convert this compound into uracil sulphonate; and the last step is 
based in a alkali desulphonation to remove bisulfate adducts from the uracil ring. 
Sodium bisulfate modification was performed using the EZ DNA Methylation-GoldTM Kit 
[Zymo Research, Orange, CA, USA] according to the manufacturer’s instructions. 1μg of 
DNA (in a total volume of 20μl), extracted from LNCaP, PNT1A and PNT2 cells, was 
submitted to the modification process. Briefly, 130μl of CT Conversion Reagent were 
included with DNA in a PCR tube. This mix was then incubated in PCR system, during 10 
min at 98ºC, and subsequent stage of 180 min at 64ºC for DNA denaturation and sodium 
bisulfite conversion. After incubation, DNA was recovered in a Zymo-SpinTM IC Column 
using 600μl of M-Binding Buffer and centrifuged for 30 sec at 10000 rpm. The column was 
washed with 100μl of M-Wash Buffer and centrifuged once again in same condition as the 
previous step. Following the M-Wash Buffer was discarded, and then 200μl of M-
Desulphonation Buffer were added for 20 min incubation’s period at room temperature. 
After discard the M-Desulphonation, the DNA was washed with M-Wash Buffer. In the 
end, the column was inserted in a 1.5ml-recovery tube and DNA was eluted in 30 + 30μl 
of distilled water. The final product was kept at -20ºC. 
 
1.8 - Bisulfite sequencing PCR (BSP)  
Using the program Methyl primer express v1.0, five pairs of primers were designed in 
order to amplify the gene region containing CpG island (end of the promoter, first exon 
and the beginning of the first intron) (Table 4). 
 
Table 4: Sequences, amplicons sizes and cycling conditions used in PCR for amplification of the 
specific primers of STEAP1. 
Oligo name Sequence (5’-3’) 
Amplicon 
size (bp) 
Annealing 
temperature 
STEAP1_met_-338fw 
STEAP1_met_+23rv 
AAAGTGTGATTTGGGAATGTT 
412 61º 
CTCCAAACCAACTACAAACCC 
STEAP1_-206fw 
STEAP1_+13rv 
TGGGGAGTTTTAGTTTTTAAGG 
219 62º 
TCAAAAAACTCACCCACTCTT 
STEAP1_-113fw 
STEAP1_+100rv 
TTTGTAGTTGGTTTGGAGGTTT 
213 62º 
TACACCCCTCCCAAAACTAA 
STEAP1_-8fw 
STEAP1_+325rv 
AAGAGTGGGTGAGTTTTTTGAA 
333 60º 
TTACCATCAAAATCCAACCTAAA 
STEAP1_+230fw 
STEAP1_+487rv 
GGGGAGAGTTAGGGATTTATAG 
257 54º 
CACCCAAATCCTAAAAAAATAA 
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After bisulfite modification, STEAP1 gene was amplified with all pairs of primers. In this 
PCR were evaluated different annealing temperatures in order to determine the best one 
of each primer pair. 
PCR reactions were performed in a 20ul reaction volume containing 2μl of DNA 
(modified), 2μl of 10x Dynazyme II Hot Start Reaction Buffer, 0.4μl dNTP mix (10 mM 
each dNTP), 0.5μl of each primer (250nM each primer), and 0.24μl of Dynazyme II 
HotStart DNA polymerase (2U/μl) (Frilabo). Reactions tubes were kept on ice at all times 
and incubated for 10 min at 94ºC, followed by 35 cycles of 30 sec at 94ºC, 30 sec at 
annealing temperature (Table 4) and 30 sec at 72ºC, followed by a final elongation of 10 
min at 72ºC on a PCR system. Amplified products were analyzed on a 2 % agarose gel 
and the results were visualized in an image analyzer (UVITEC - Cambridge). 
 
1.9 - Direct sequencing (Bisulfite) and analysis of sequences 
PCR products were purified with kit Illustra GFX (GE Healthcare). The columns were put 
in the respective “collection tube”, next 500ul of “Capture buffer type 3” was added to the 
column and then was joined it the amplification product. The columns were centrifuged 
during 1 min at 12000 rpm. The flow-through was discarded and the columns were placed 
back into the collection tube. Next, 500ul of “Wash Buffer type 1” was added to each 
column. Subsequently, the columns were again centrifuged for 1 min at 12000 rpm. The 
PCR Clean-up Columns were placed into a new 1.5ml microcentrifuge tube, and 30ul of 
“Elution Buffer type 6”, was added, incubated at room temperature over 5 min and, at last, 
the columns were centrifuged for 5 min at 12000 rpm. Purified products were analyzed on 
a 2 % agarose gel and the results were visualized in an image analyzer. 
After purification, the purified PCR products were sequenced using Sequencing PCR kit 
(Applied Biosystems). Two tubes were used for each sample, one for the forward reaction, 
and another for the reverse. Sequencing PCR reactions were performed in a 10 ul 
reaction volume containing 1.9μl of Big Dye Buffer, 1μl Big Dye Mix v1.1, 0.35μl of each 
primer (350nM each primer) and 1 to 3 ul of DNA that depend on the intensity of each 
sample previously visualized on agarose gel. Reaction tubes were kept on ice and 
incubated for 2 min at 96ºC, followed by 30 cycles of 15 sec at 96ºC, 15 sec at 50ºC, and 
4 min at 60ºC, on a PCR system.  
The PCR products were purified with Illustra Sephadex G-50 fine. The columns were put 
in the respective tube of 2mL and was added the Sephadex to each column. The columns 
were centrifuged for 4 min at 4400 rpm. The columns with sephadex were placed into a 
new 1.5ml microcentrifuge tube and were added 10ul of Sequencing PCR product. The 
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columns were centrifuged again during 4 min at 4400 rpm and the sephadex was 
removed of the columns. Finally, it was added 12ul of formamide to purified product and 
transferred to sequencer tubes. 
After sequencer analysis, it was determined the ratio of methylation by the formula [height 
C / (height C + height T)] x 100. 
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2 – STEAP1 protein expression in human prostate cancer 
 
2.1 - Patients and tissue samples 
The human tissue samples (N=102) are derived from prostatectomy and were gently 
provided by pathology service of “Hospital Geral de Santo António – Porto”. The patients 
did not receive preoperative chemotherapy or any other type of treatment. The detailed 
characteristics of patients are described in Table A1 in appendix. 
 
2.2 - Construction of TMAs 
For the construction of a TMA, the number of cases and cores that were used in the 
generation of the TMA were determined and then it was reviewed all the slides and was 
marked the areas of interest. For this, TMA building was used a core size of the 2 mm and 
a maximum of 12 cores per case. Liver tissues were placed in TMA block for quality 
control and to address tumor heterogeneity.  
The block from which a core was taken is referred to as the donor block, and the area of 
this donor block from which the core was removed for TMA, was selected by a 
pathologist. The block, in which the cores were placed, is referred to as the recipient 
block. Next, we cut sections of 4μm of each block, using a microtome, and placed in a 
solution of cold water and ethanol to be extension of the paraffin followed by a solution of 
warm water (42ºC). Finally, they were removed with the help of a slide and were left to dry 
(Figure 18). Prior to performe immunohistochemistry technique, the slides (with respective 
sections of each TMA) were placed in “hothouse” at 60ºC overnight, which allowed the 
melting of the paraffin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Steps involved in TMA construction [adapted from (Giltane 2004)]. 
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2.3 - Immunohistochemistry and analysis of STEAP1 immunoreactivity 
The immunohistochemical analysis was carried out in TMAs of human prostate cancer, 
BPH, PIN and non-neoplastic tissue samples. Firstly, the slides for immunohistochemical 
were deparaffinized in xilol and rehydrated in decreasing solution of ethanol. In order to 
block the activity of endogenous peroxidases, 2ml of H2O2 (3%) were added to each slide. 
After 5 min, these slides were washed in PBS-T (Phosphate Buffered Saline-Tween 20) 
during 2 min, and added  goat serum 5% (Santa Cruz Biotechnology, Santa Cruz, USA) to 
prevent any nonspecific binding sites for 30 min, a new wash in PBS-T was done for 5 min 
with agitation, and then, the samples were incubated with primary antibody α-STEAP1 (H-
105, Santa Cruz Biotechnology, Santa Cruz, USA) diluted 1:50 in PBS (Phosphate 
Buffered Saline) with 1% BSA for 1 h at room temperature. The slides were washed again 
for 10 min with agitation, and they were incubated with secondary antibody α-rabbit 
(diluted 1:20 in PBS with 1%BSA) for 1 h at room temperature. After new wash for 10 min 
in PBS-T with agitation, the slides were incubated with “ExtrAvidin-Peroxidase” for 30 min. 
Then, it was washed again in PBS-T for 10 min with shaking and 100μl 3,3-
Diaminobenzidine (DAB) (Sigma) were added in each slide, until the development of 
appropriate coloration. The slides were passed through water and immersed in 
hematoxylin (Hematoxylin 7211, Richard-allan Scientific) for 1 – 2 min. Finally, the slides 
were washed for 10 sec, and subjected to a process of gradual dehydration, in which it 
was added 1 – 2 drops of the permanent mounting medium (Entellan, Merck (103602)) 
and covered with a coverslip.  
 
STEAP1 immunoreactivity was assessed semiquatitatively using a grade score system, 
based on the intensity of staining and percentage of stained cells. The intensity was 
divided into “0” (no staining), “1” (low staining) and “2” (high staining). The percentage of 
stained cells was divided into “0” (no stained cells), “1” (up to 25% of stained cells), “2” 
(between 25-50% of stained cells) and “3” (more than 50% of stained cells).  
 
In order to calculate the final score, the percentage of stained cells and intensity were 
multiplied, giving the following scores (0, 1, 2, 3, 4 e 6). Then, these score values were 
grouped into low immunoreactivity (score 0 and 1), moderate immunoreactivity (score 2 
and 3), and high immunoreactivity (score 4 and 6). 
 
2.4 – Statistical analysis 
Association between STEAP1 immunoreactivity and histologic diagnosis or clinic-
pathologic data of patients was analyzed by Chi-square statistical test. All data were 
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analyzed using SPSS version 17.0 software. p<0.05 was considered to be statistically 
different. 
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RESULTS / DISCUSSION 
 
1 - Expression analysis of STEAP1 in human prostate cell lines. 
 
To analysis the expression of STEAP1 genes in non-neoplastic (PNT1A and PNT2) and 
neoplastic (LNCaP and PC3), PCR reactions were performed using specific primers to 
STEAP1, STEAP1B1 and STEAP1B2 gene. A negative control was used for each primers 
set, containing only the mix without cDNA (Figure 19).  
 PNT1A   PNT2   LNCaP      PC3       NC 
  
 
 
 
 
Figure 19: PCR analysis of STEAP1, STEAP1B isoform 1 and STEAP1B isoform 2 mRNA 
expression in PNT1A, PNT2, LNCaP and PC3 prostate cell lines. 1, 5, 9 and 13 – STEAP1; 2, 6, 
10 and 14 – STEAP1B1; 3, 7, 11 and 15 – STEAP1B2; 4, 8, 12 and 16 – GAPDH; 17, 18, 19 and 
20 – STEAP1, STEAP1B1, STEAP1B2 and GAPDH negative control, respectively.  
 
As depicted in figure 19, the expression of STEAP1 was detected in all cell lines, but 
neoplastic cell lines (LNCaP and PC3) seems to present higher levels of STEAP1 than 
non-neoplastic cell lines (PNT1A and PNT2). STEAP1B1 mRNA is slightly expressed in 
PNT2 and PC3 cells, but no expression was detected in LNCaP and PNT1A cells. 
Regarding the STEAP1B2 expression, it was observed that LNCaP and PC3 cells present 
a higher level  when compared to PNT1A and PNT2 cells.  
The results obtained by conventional PCR showed that the STEAP1 mRNA is more 
expressed in all prostate cell lines when compared to STEAP1B1 or STEAP1B2, 
suggesting that the main physiologic roles may be attributed to STEAP1. However, it is 
necessary to analyze the expression of STEAP1B1 and STEAP1B2 proteins using 
specific antibodies. In case of expression of these proteins, it is necessary to develop 
functional studies in order to clarify the role of each STEAP1 isoform in prostate cells. 
Considering these results obtained by conventional PCR, it was quantified the expression 
of STEAP1 by Real Time PCR in prostate cell lines. The data showed that STEAP1 is 
highly expressed in LNCaP, followed by PC3, PNT1A and PNT2 (Figure 20). 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1500bp  
 
500bp 
300bp 
200bp 
17 18 19 20 
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Figure 20: Analysis of STEAP1 mRNA expression in PNT1A, PNT2, LNCaP and PC3 cells by 
Real-time PCR. STEAP1 mRNA expression was normalized with GAPDH housekeeping gene. 
 
As expected, our results show that STEAP1 is over-expressed in neoplastic prostate cell 
lines when compared to non-neoplastic. As previously described by (Hubert 1999), 
LNCaP present higher levels of STEAP1 than PC3 cells. Taking into account that LNCaP 
cells are AR-positive and PC3 are AR-negative, this differential expression suggests that 
STEAP1 expression may be regulated by androgens. However, contrarily as expected, 
our research group demonstrated that STEAP1 gene is slightly down-regulated by 
androgens in LNCaP cells (Gomes (in press)). 
In order to confirm that the higher levels of STEAP1 mRNA in LNCaP cells also 
corresponds to higher levels of protein, western blot analysis was carried out using total 
protein extracted from LNCaP, PC3, PNT1A, and PNT2 cells. The results show one 
immunoreactive band of 36 KDa in LNCaP and PC3 cells, whereas in PNT1A cells two 
immunoreactive bands of 36 and 30 KDa were detected (Figure 21). Regarding the PNT2 
cells, no immunoreactive bands were detected. The immunoreactive band of 36 KDa 
corresponds to the molecular weight of STEAP1, as previously reported by others (Hubert 
1999; Vaghjiani 2009).  
Our results show that STEAP1 protein is also over-expressed in LNCaP cells in 
comparison with the other cell lines. . In opposition to observed at mRNA level, only a 
slight expression of STEAP1 protein is detected in PC3 cells, suggesting that others 
mechanisms may be involved, such as regulation of translation, and stability of mRNA 
and/or protein.  Regarding the immunoreactive band of 30 KDa detected in PNT1A cells, it 
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is liable to speculate that may correspond to STEAP1B2 isoform, which is in accordance 
with the predicted molecular weight for STEAP1B2 protein. However, it is necessary 
develop others approaches to confirm it, as for example proteomics and development of 
specific antibodies against each STEAP1 isoform. 
  
 
 
 
 
 
Figure 21: Western blot analysis of STEAP1 protein expression using an anti- STEAP1 polyclonal 
antibody (1:300) in PNT1A, PNT2, LNCaP and PC3 cell lines.  
 
2 - Analysis of methylation of DNA in cell lines (LNCaP, PNT1A and PNT2) 
 
As described above, STEAP1 gene is over-expressed in LNCaP cells when compared to 
non-neoplastic cells (PNT1A and PNT2). However, the mechanisms underlying its up-
regulation in cancer remain to be explored. As epigenetic mechanisms have been 
described as involved in prostate cancer, our aim was to assess whether epigenetic 
mechanism are involved in regulation of STEAP1 gene expression.  
As described in Materials and Methods, the confirmation of cell-cultures mycoplasm-free 
was carried out by PCR (appendix, Figure A2). After bisulfite modification, we sequenced 
part of the STEAP1 gene, namely where there are more CpG islands. Through the five 
pairs of primers, it was possible, in total, to analyze the ratio of methylation of 61 CpG 
islands (see Figure A3 of appendix). In figure 22 are depicted the schematic 
representation of each CpG island analyzed. 
1 2 3 4 
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 CpG Island 
LNCaP 
cell line 
                               
                              
  11.48% methylated, 85.25% partially methylated and 0% non-methylated. 
 
 CpG Island 
PNT1 cell 
line 
                               
                              
 14.75% methylated, 77.05% partially methylated and 3.28% non-methylated. 
 
 CpG Island 
PNT2 cell 
line 
                               
                              
 24.59% methylated, 68.85% partially methylated and 1.64% non-methylated. 
 
 
Legend: 
 
 
Figure 22: CpG methylation in promoter region of STEAP1 gene. The methylation status of CpG was analyzed in LNCaP, PNT1A and PNT2 cells. 
Methylated Non-methylated Partially methylated Not analyzed 
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Some primers did not work properly well and for this reason in each cell line, there is 
always “CG” dinucleotides that we cannot analyze. However, it seems there is no 
significant difference in DNA methylation of “CpG” island between neoplastic (LNCaP) and 
non-neoplastic (PNT1A and PNT2) prostate cells. So, the over-expression of STEAP1 
mRNA should not be explained by hypomethylation at promoter region of STEAP1 gene. 
During sequencing, we found that some “CpG” island were not present in the sequence of 
STEAP1 gene. Probably, this may be due to the existence of the other gene, STEAP1B1. 
In fact, by overlapping the sequences of STEAP1 and STEAP1B genes (see Figure A4 of 
Appendix) it was observed that both sequences differ in a few nucleotides and some of 
them coincide exactly with additional “CG” dinucleotide, which are detected during the 
STEAP1 sequencing. However, these results should be confirmed through another 
strategy. 
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3 - Expression analysis of STEAP1 in human prostate TMAs 
 
3.1 – Clinic and pathological characteristics 
Tissue samples from 63 prostate cancer, 41 adjacent normal tissue (ANT), 7 PIN lesions, 
and 39 BPH were analyzed. The clinical characteristics of patients are illustrated in table 
5. 
 
Table 5: Clinic-pathological data of patients from which tissue samples were obtained. 
 
 
 
 
 
 
 
 
 
(The lack of some values is due to the absence of some data in the clinical records of patients. 
Abbreviations: BPH – Benign Prostatic Hyperplasia, n.a – Not Applicable). 
 
3.2 - TMAs 
In order to analyze the STEAP1 expression in neoplastic tissue and non-neoplastic 
tissues of the prostate, immunohistochemistry method was carried out in TMAs of human 
prostate. With the aid of TMA block constructs, which correspond to tissues of the 
prostate tumor (see Figure A5 - A and B in appendix) and BPH (see Figure A5 - C and D 
in appendix), several slides were analyzed using a specific antibody against STEAP1 
protein through of immunohistochemistry technique (see Figures A6, A7 and A8 in 
appendix). 
 
3.3 - STEAP1 protein expression in prostate tissues 
STEAP1 immunoreactivity was classified according to a score scale established for this 
parameter, which takes into account the intensity of the signal and percentage of stained 
cells. Representative images of positive cases with low, moderate and high STEAP1 
immunoreactivity are shown in figure 23. 
Clinic-pathological features Prostate cancer BPH 
Patients (n) 63 39 
Mean age (years) 64 (41 – 83) 70 (41 – 88) 
Total-PSA (ng/mL), mean 8.93 (3.24 – 77.91) 3.73 (0.17 – 15.4) 
Gleason (n) % 
<7 (16/63) 25.4% n.a 
≥7 (47/63) 74.6% n.a 
TNM (n) % 
T2a (3/32) 9.4% n.a 
T2b and T2c  (20/32) 62.5% n.a 
T3 (9/32) 28.1% n.a 
Bone Metastasis (n) % 
Absence (23/25) 92% n.a 
Present (2/25) 8% n.a 
B 
A  
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Figure 23 - STEAP1 immunoreactivity in prostate cancer TMAs. Representative images of: A - 
Low, B - Moderate and C - High STEAP1 immunoreactivity are shown in prostate carcinoma. 
 
In order to evaluate whether STEAP1 immunorecativity differs between histologic 
diagnosis, several cases were analyzed using immunochemistry method. A representative 
picture of STEAP1 immunoreactivity in ANT, BPH, PIN lesions, and prostate cancer are 
showing in figure 24. 
C 
A 
B 
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Figure 24 - The immunohistochemical expression of STEAP1 in adjacent normal glands tissue, 
BPH, PIN and prostate cancer. A - Image that depict the STEAP1 expression in non-neoplastic 
prostate tissue, (with reasonable staining). B - Image representative of STEAP1 expression in 
benign hyperplasia prostate tissue, (with a reasonable staining). C - Images representatives of 
STEAP1 expression in PIN tissue. D and E - Representatives images of STEAP1 expression in 
prostate tumor tissue, (D – There is a stronger staining in the cytoplasm of cells, E – There is a 
strong staining in the membrane of cells). These images are observed in an optic microscope, ate 
a magnification of 40x.  
 
Regarding to the BPH, the results shows that STEAP1 is expressed in basal cells (Figure 
24, image B). Taking into account that basal cells may act as reservoir of stem cells and 
A B 
C D 
E 
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STEAP1 and STEAP2 are differently expressed in mesenchymal stem cells from bone 
morrow (Vaghjiani 2009), it is liable to speculate that STEAP1 may be involved in 
differentiation process of prostate cells. However, more studies are required to clarify the 
expression and role of STEAP1 in prostate stem cells. Tumor tissues positive for STEAP1 
shows a brown staining in cytoplasm (Figure 24, image D) and membrane (Figure 24 
image E) of the epithelial cells. These results are consistent with previous studies, which 
indicate that STEAP1 is localized in plasma membrane of epithelial cells of the prostate, 
especially in cell junctions (Hubert 1999; Challita-Eid 2007). Besides cell membrane, 
STEAP1 is also uniformly expressed in cytoplasm of epithelial cells. However, we observe 
that the STEAP1 expression in cell membrane is similar to found in cytoplasm, i.e., there 
is no statistical difference between cell membrane and cytoplasm (data not shown). Even 
with low intensity, it is also observed that STEAP1 is expressed in stromal cells. 
As described in material and methods, the STEAP1 immunoreativity in prostate cells was 
grouped into three groups, low, moderate and high. Using the qui-square statistical test 
(IBM SPSS Statistic 20), it was possible to investigate the differences of STEAP1 
immunoreactivity between the different types of histologic diagnosis (Table 6). This 
analysis showed that STEAP1 is over-expressed in high percentage of tumor tissues and 
PIN lesions when compared to BPH or ANT. These results are in agreement with 
previously described by Li and colleagues (Li 2004). However they only evaluated the 
STEAP1 expression in prostate cancer and BPH, and their results are not clearly 
understood.  
 
Table 6: Distribution of STEAP1 immunoreactivity in ANT, BPH, PIN lesions, and prostate cancer. 
 
 
* p value corresponds to comparisons between prostate cancer and each histologic diagnosis. 
 
Of our knowledge, this is the first report showing that STEAP1 is over-expressed in PIN 
lesions. Comparing the STEAP1 immunoreactivity between tumors and PIN lesions, no 
statistical differences were obtained, suggesting that the deregulation of STEAP1 
expression may occur even before the development of cancer.  
 
 STEAP1 immunoreactivity  
Histologic 
diagnosis 
Negative or low  Moderate  High P (Chi-square)* 
Prostate cancer 11.11% (7/63) 36.51% (23/63) 52.38% (33/63) ------------ 
PIN 0% (0/7) 14.29% (1/7) 85.71% (6/7) 0.236 
BPH 97.44% (38/39) 2.56 % (1/39) 0% (0/39) <0.0001 
ANT 73.17% (30/41) 19.51% (8/41) 7.32% (3/41) <0.0001 
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3.4 - Relationship between STEAP1 immunoreactivity and the clinic-pathological 
data 
We further assessed the association between STEAP1 expression and clinic-pathological 
data of the patients, such as age, total-PSA and free-PSA value, Gleason score, stage 
and presence of bone metastases (Table 7). 
 
Table 7: Correlations between STEAP1 expression in prostate tissues samples and clinico-
pathological data. 
 
 
 
 STEAP1 immunoreactivity 
 
 
Variable (n) 
Negative or 
low  
Moderate  High  
P (Chi-
square) 
Age      
<55 years 
63 
0 % (0/9) 11.11% (1/9) 88.89% (8/9) 
0.076 55 to 65 years 9.09% (3/33) 48.48% (16/33) 42.42% (14/33) 
>65 years 19.05 % (4/21) 28.57 % (6/21) 52.38% (11/21) 
Total-PSA      
< 4 ng/ml 
36 
16.67% (1/6) 16.67% (1/6) 66.67 % (4/6) 
0.892 4 to 10 ng/ml 16% (4/25) 36% (9/25) 48% (12/25) 
>10 ng/ml 20% (1/5) 40% (2/5) 40% (2/5) 
Free-PSA      
< 10% 
27 
10% (1/10) 30% (3/10) 60% (6/10) 
0.490 
10 to 15% 0% (0/8) 37.5% (3/8) 62.5% (5/8) 
15 to 20% 25% (1/4) 50% (2/4) 25% (1/4) 
20 to 25% 40% (2/5) 20% (1/5) 40% (2/5) 
Gleason      
< 7 
63 
31.25% (5/16) 43.75% (7/16) 25% (4/16) 
0.004 
≥ 7 4.26% (2/47) 34.04% (16/47) 61.7% (29/47) 
TNM      
T2a 
32 
33.33% (1/3) 33.33% (1/3) 33.33% (1/3) 
0.372 T2b and T2c 5% (1/20) 55% (10/20) 45% (9/20) 
T3 11.11% (1/9) 22.22% (2/9) 66.67% (6/9) 
Bone 
metastasis 
     
Absence 
25 
8.70% (2/23) 43.48% (10/23) 47.83% (11/23) 
0.908 
Present 0% (0/2) 50% (1/2) 50% (1/2) 
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Most patients are between 55 and 65 years old. Patients under 55 years old have mainly 
a high expression of STEAP1, patients between 55 and 65 years are moderate 
expression and over 65 years old have a high expression of STEAP1 (p=0.076). 
Comparing the values of PSA with the STEAP1 expression, was observed that most 
patients presented a PSA value between 4 and 10 ng/ml, and all PSA levels are 
correlation with high expression of STEAP1 (p=0.892). Most of the patients with Gleason 
scores below 7 have a moderate expression of STEAP1, whereas patients with Gleason 
scores equal or superior to 7 present mostly a high STEAP1 expression (p=0.004). As for 
the stage, most patients have a stage T2b and T2c with a moderate STEAP1 expression 
while patients with a stage T3a have a high expression (p=0.372). The largest part 
patients has no bone metastases, which a largely relates to a moderate or high 
expression of STEAP1 (p=0.908). 
Looking at the outcome of the ratios obtained with chi-square test and the significance (p 
value) that we obtained, we could affirm that the levels of STEAP1 are associated with 
“Gleason score”. However, it was not observed an association between the variable 
“STEAP1 expression” and the variables “age”, “total-PSA”, “free PSA value”, “staging” and 
“bone metastases”. The size of some samples and the fact that not all patients analyzed 
have all information available and described, may be on the basis of the lack of 
association between certain variables. So, this was considered a limitation of this study. 
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CONCLUSION 
 
In this study, we can conclude that STEAP1 is over-expressed in neoplastic cells lines 
when compared to non-neoplastic prostate cells, being highly expressed in LNCaP cells.  
Although the regulation of STEAP1 does not seem to involve epigenetic mechanisms, it is 
necessary to use other approach to confirm it.  
STEAP1 is over-expressed in human prostate cancer cases and PIN lesions when 
compared ANT or BPH. STEAP1 expression in prostate cancer seems to correlates 
positively with Gleason score, but not with age, total-PSA, free-PSA, TNM and bone 
metastasis. 
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FUTURE PERSPECTIVES 
 
To reach all the aims of this thesis is still needed to complete some gaps. Concerning to 
the STEAP1 regulation by epigenetic mechanisms, it is required to use another strategy to 
evaluate whether there are differences in methylation pattern between LNCaP and non-
neoplastic prostate cells. For example, the PCR products could be cloned into expression 
vector and transformed with competent cells. Next, plasmid vector should be extracted 
from several colonies and sequenced in order to estimate the methylation pattern of 
STEAP1 gene promoter region. This strategy has been used by several authors to 
determine the methylation degree in promoter region of genes (Suh 2002; Liu 2010). 
Besides the involvement of epigenetic mechanisms in regulation of STEAP1 gene, it 
would be important to explore other possible mechanisms that could be involved in its 
over-expression in prostate cancer, such as to evaluate the stability of STEAP1 mRNA 
and protein between neoplastic and non-neoplastic prostate cells. 
Regarding the expression of STEAP1 protein in prostate cancer tissues, would be 
important to increase the number of samples in order to better clarify the clinical 
significance of STEAP1 expression in prostate cancer. In addition, it would be interesting 
to develop studies in order to analyze the impact of STEAP1 protein expression in 
patient’s outcome. 
References 
52 
 
REFERENCES  
 
Abrahamsson, P. A., Lilja, H., Oesterling, J.E. (1997). "Molecular forms of serum prostate-
specific antigen. The clinical value of percent free prostate-specific antigen." Urol Clin 
North Am 24(2): 353–365. 
  
Alves, P. M., Faure, O., Graff-Dubois, S., Cornet, S., Bolonakis, I., Gross, D.A., Miconnet, 
I., Chouaib, S., Fizari, K.,  Soria, J.C., Lemonnier, F.A., Kosmatopoulos, K. (2005). 
"STEAP, a prostate tumor antigen, is a target of human CD8+ T cells." Cancer Immunol 
Immunother 55(12): 1515-1523. 
  
Andriole, G. L., Crawford, E.D., Grubb Rl, 3rd., Buys, S.S., Chia, D., Church, T.R., Fouad, 
M.N., Gelmann, E.P., Kvale, P.A., Reding, D.J., Weissfeld, J.L., Yokochi, L.A., O'brien, B., 
Clapp, J.D., Rathmell, J.M., Riley, T.L., Hayes, R.B., Kramer, B.S., Izmirlian, G., Miller, 
A.B., Pinsky, P.F., Prorok, P.C., Gohagan, J.K., Berg, C.D (2009). "Mortality results from a 
randomized prostate-cancer screening trial." N Engl J Med 360(13): 1310–1319. 
  
Atkinson AJJr, C. W., DeGruttola, V.G., DeMets, D.L., Colburn, W.A., Downing, G.J., 
Hoth, D.F., Oates, J.A., Peck, A.C., Schooley, R.T, Spilker, B.A., Woodcock, J., Zeger, 
S.L. (2001). "Biomarkers and surrogate endpoints: Preferred definitions and conceptual 
framework". Biomarkers Definitions Working Group. Clin Pharmacol Ther 69(3): 89–95. 
  
Attard, G., Clark, J., Ambroisine, L., Fisher, G., Kovacs, G., Flohr, P., Berney, D., Foster, 
C.S, Fletcher, A., Gerald, W.L., Moller, H., Reuter, V., De Bono, J.S., Scardino, P., 
Cuzick, J., Cooper, C.S.  (2008). "Duplication of the fusion of TMPRSS2 to ERG 
sequences identifies fatal human prostate cancer." Oncogene 27(3): 253-263. 
  
Baltaci, S., Orhan, D., Ozer, G., Tolunay, O., Gögõüs, O. (2000). "Bcl-2 proto-oncogene 
expression in low- and high-grade prostatic intraepithelial neoplasia." BJU Int 85(1): 155-
159. 
  
Bostwick, D. G. (1996). "Prospective origins of prostate carcinoma. Prostatic intraepithelial 
neoplasia and atypical adenomatous hyperplasia." Cancer 78(2): 330-336. 
  
Bostwick, D. G., Amin, M.B., Dundore, P., Marsh, W., Schultz, D.S. (1993). "Architectural 
patterns of high-grade prostatic intraepithelial neoplasia. " Hum Pathol 24(3): 298-310. 
  
References 
53 
 
Bostwick, D. G. and Brawer, M.K. (1987). "Prostatic intra-epithelial neoplasia and early 
invasion in prostate cancer." Cancer 59(4): 788-794. 
  
Bostwick, D. G. and Qian, J. (2004). "High-grade prostatic intraepithelial neoplasia." Mod 
Pathol 17(3): 360-379. 
  
Bova, G. S., Beaty, T.H., Steinberg, G.D., et al (1993). "Hereditary prostate cancer: 
epidemiologic and clinical features." J Urol 150: 797–802. 
  
Boyle, P., Severy, G., Gilles, G.G. (2003). "The epidemiology of prostate cancer." Urol 
Clin North Am 30(2): 209-217. 
  
Brooks, J. D., Weinstein, M., Lin, X., Sun, Y., Pin, S.S., Bova, G.S., Epstein, J.I., Isaacs, 
W.B., Nelson, W.G. (1998). "CG island methylation changes near the GSTP1 gene in 
prostatic intraepithelial neoplasia." Cancer Epidemiol Biomarkers Prev 7(6): 531-536.  
 
Byar, D. P. and Mostofi (1972). "Carcinoma of the prostate: prognostic evaluation of 
certain pathologic features in 208 radical prostatectomies." Cancer 30(1):5-13. 
   
Cancer.Net (2012). "Prostate Cancer - Risk Factors and Prevention."  American Society of 
Clinical Oncology. 
  
Carter, H. B., Pearson, J.D., Metter, E.J., Brant, L.J., Chan, D.W., Andres, R., Fozard, 
J.L., Walsh, P.C. (1992). "Longitudinal evaluation of prostate-specific antigen levels in 
men with and without prostate disease." JAMA 267(16): 2215-2220. 
  
Catalona, W. J., Smith, D.S., Ratliff, T.L., Basler, J.W. (1993). "Detection of organ-
confined prostate cancer is increased through prostate-specific antigen-based screening." 
JAMA 270(8): 948-954. 
 
Cerveira, N., Ribeiro, F.R., Peixoto, A., Costa, V., Henrique, R., Jerónimo, C., Teixeira, 
M.R. (2006). "TMPRSS2-ERG gene fusion causing ERG overexpression precedes 
chromosome copy number changes in prostate carcinomas and paired HGPIN lesions." 
Neoplasia 8(10): 826-832. 
 
Challita-Eid, P. M., Morrison, K., Etessami, S., An, Z. , Morrison, K.J., Perez-Villar, J.J.,  
Raitano, A.B., Jia, X.C., Gudas, J.M., Kanner, S.B., Jakobovits, A. (2007). "Monoclonal 
References 
54 
 
antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular 
communication in vitro and growth of human tumor xenografts in vivo." Cancer Res 
67(12): 5798-5805. 
  
Chu, T.M. (1997). "Prostate-specific antigen and early detection of prostate cancer." 
Tumor Biol 18(2): 123-134. 
 
Costello, J. F., Frühwald, M. C., Smiraglia, D. J., Rush, L.J., Robertson, G.P., Gao, X., 
Wright, F.A., Feramisco, J.D., Peltomäki, P., Lang, J.C., Schuller, D.E., Yu, L., Bloomfield, 
C.D., Caligiori, M.A., Yates, A., Nishikawa, R., Su Huang, H., Petrelli, N.J., Zhang, X., 
O'Dorisio, M.S., Held, W.A., Cavenee, W.K., Plass, C. (2000). "Aberrant CpGisland 
methylation has non-random and tumour-type-specific patterns." Nat Genet 24(2): 132–
138. 
   
Das, B., Tsuchida, R., Malkin, D., Koren, G., Baruchel, S., Yeger, H. (2008). "Hypoxia 
enhances tumor stemness by increasing the invasive and tumorigenic side population 
fraction." Stem Cells 26(7): 1818–1830. 
  
Das, D., Wojno, K., Imperiale, M.J. (2008). "BK virus as a cofactor in the etiology of 
prostate cancer in its early stages." J Virol 82(6): 2705-2714. 
  
DeMarzo, A. M., Nelson, W.G., Isaacs, W.B., Epstein, J.I. (2003). "Pathological and 
molecular aspects of prostate cancer " Lancet 361(9361):955-964. 
  
Dillman, R. O. and Williams, T. (1994). "Value of prostate cancer screening in a 
comprehensive community cancer centre." Cancer Invest 12(5): 456–462. 
  
Ehrlich, M. (2002). "DNA methylation in cancer: too much, but also too little." Oncogene 
21(35): 5400–5413. 
  
Ellis, W. J. and Lange, P.H. (1994). "Prostate cancer." Endocrinol Metab Clin North Am 
23(4): 809–824. 
  
Emmert-Buck, M. R., Vocke, C.D., Pozzatti, R.O., Duray, P.H., Jennings, S.B., Florence, 
C.D., Zhuang, Z., Bostwick, D.G., Liotta, L.A., Linehan, W.M. (1995). "Allelic loss on 
chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia." Cancer Res 
55(14): 2959-2962. 
References 
55 
 
Epstein, J. I. (1995). "Diagnostic criteria of limited adenocarcinoma of the prostate on 
needle biopsy." Hum Pathol 26(2):223-229. 
  
Epstein, J. I. (2000). "Gleason score 2-4 adenocarcinoma of the prostate on needly 
biopsy: a diagnosis that should not be made." Am J Surg Pathol 24(4): 477-478. 
  
Epstein, J. I. and Netto, G.J. (2002). Biopsy Interpretation of the Prostate. Four edition. 
Philadelphia, Lippincott Williams & Wilkins. 
  
Epstein, J. I. (2011). "Update on the gleason grading system." Ann Pathol 31(5 Suppl): 
S20-S26. 
  
Epstein, J. I., Walsh, P.C., Carmichael, M., Brendler, C.B. (1994). "Pathological and 
clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer." 
JAMA 271(5):368-374. 
  
Epstein, J. I. and Potter, S.R. (2001). "The pathologic interpretation and significance of 
prostate biopsy findings: implications and current controversies." J Urol 166(2):402-410. 
  
Evren, S., Dermen, A., Lockwood, G., Fleshner, N., Sweet, J. (2011). "mTOR-RAPTOR 
and 14-3-3sigma immunohistochemical expression in high grade prostatic intraepithelial 
neoplasia and prostatic adenocarcinomas: a tissue microarray study." J Clin Pathol 64(8): 
683-688. 
  
Facio, F., Kashiwabuschi, R., Nishi, Yutaro., Leao, R., McDonnell,  P., Burnett, A. (2010). 
"Benign Prostatic Hyperplasia. Clinical Treatment Can Complicate Cataract Surgery." Int 
Braz J Urol 36(5): 563-570. 
  
Feinberg, A. P. and Vogelstein, B. (1983). "Hypomethylation distinguishes genes of some 
human cancers from their normal counterparts." Nature 301(5895): 89–92. 
 
Ferlay, J., Parkin, D.M., Steliarova-Foucher, E. (2010). " Estimates of cancer incidence 
and mortality in Europe in 2008". European Journal of Cancer 46: 765-781. 
  
Foster, C. S. (2000). Pathology of benign prostatic hyperylasia. Prostate Suppl 9:4-14. 
   
References 
56 
 
Frigola, J., Song, J., Stirzaker, C., Hinshelwood, R.A., Peinado, M.A., Clark, S.J. (2006). 
"Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across 
an entire chromosome band." Nat Genet 38(5): 540–549. 
 
Garcia-Hernandez, M. L., Gray, A., Hubby. B., Kast, W.M. (2007). "In vivo Effects of 
Vaccination with Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate 
Antigen for Treating Prostate Cancer." Cancer Res 67(3): 1344-1351. 
Giltane, J. M. and. Rimm, D.L. (2004). "Technology Insight: identification of biomarkers 
with tissue microarray technology." Nat Clin Pract Oncol 1(2): 104-111. 
  
Gleason, D. F. (1966). "Classification of prostate carcinomas." Cancer Chemother Rep 
50: 125-128. 
  
Gleason, D. F. and Mellinger, G.T. (1974). "Prediction of prognosis for prostatic 
adenocarcinoma by combined histologic grading and clinical staging." J Urol 111(1):58-64. 
  
Goelz, S. E., Vogelstein, B., Hamilton, S. R., Feinberg, A.P. (1985). "Hypomethylation of 
DNA from benign and malignant human colon neoplasms." Science 228(4696): 187–190. 
 
Gomes, I.M., Maia, C.J., Santos, C.R. (2012). "STEAP proteins: from structure to 
applications in cancer therapy." Mol Cancer Res 10(5): 573-587. 
 
Gomes, I.M., Santos, C., Socorro, S., Maia, C.J. Six transmembrane epithelial of the 
prostate 1 is down-regulated by sex hormones in prostate cells. The Prostate (In press). 
  
Gopalan, A., Leversha, M.A., Satagopan, J.M., Zhou, Q., Al-Ahmadie, H.A., Fine, S.W., 
Eastham, J.A., Scardino, P.T., Scher, H.I., Tickoo, S.K., Reuter, V.E., Gerald, W.L. 
(2009). "TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by 
prostatectomy." Cancer Res 69(4): 1400-1406. 
  
Grönberg, H. (2003). Prostate cancer epidemiology. Lancet. 361(9360): 859-864. 
  
Grunewald, T., Diebold, I., Esposito, I. Plehm, S., Hauer, K., Thiel, U. da Silva-Bittkus, P., 
Neff, F., Unland, R., Müller-Tidow, C., Zobywalski, C., Lohring, K., Lewandrowski, U., 
Sickmann, A., Prazeres da Costa, O., Görlach, A., Cossarizza, A., Butt, E., Richter, G.H., 
Burdach, S. (2011). "STEAP1 Is Associated with the Invasive and Oxidative Stress 
Phenotype of Ewing Tumors." Mol Cancer Res 10(1): 52-65. 
References 
57 
 
Haas, G. P. (1994). "Epidemiology of early prostate cancer (introduction)." In vivo 8(3): 
403-405. 
  
Häggman, M. J., Macoska, J.A., Wojno, K.J., Oesterling, J.E. (1997). "The relationship 
between prostatic intraepithelial neoplasia and prostate cancer: critical issues." J Urol 
158(1): 12-22. 
  
Harris, R. P., Lohr, K.N., Beck, R., Fink, K., Godley, P., Bunton, A. (2001). "Screening for 
Prostate Cancer [Internet]." (Prepared by the Research Triangle Institute-University of 
North Carolina Evidence-based Practice Center under Contract no. 290-97-0011). 
Rockville, MD: Agency for Healthcare Research and Quality 16. 
   
Hessels, D., Klein Gunnewiek, J.M., Van Oort, I., Karthaus, H.F., Van Leenders, G.J., Van 
Balken, B., Kiemeney, L.A., Witjes, J.A. Schalken, J.A. (2003). "D3(PCA3)-based 
molecular urine analysis for the diagnosis of prostate cancer." Eur Urol 44(1): 8–15. 
  
Hill, R. P., Marie-Egyptienne, D.T., Hedley, D.W. (2009). "Cancer stem cells, hypoxia and 
metastasis, ." Semin Radiat Oncol 19(2): 106–111. 
  
Hoffman, R. M., Clanon, D.L., Littenberg, B., Frank, J.J., Peirce, J.C. (2000). "Using the 
free-to-total prostate-specific antigen ratio to detect prostate cancer in men with 
nonspecific elevations of prostate-specific antigen levels." J Gen Intern Med. 15(10): 739–
748. 
  
Hubert, R. S., Vivanco, I., Chen, E., Rastegar, S., Leong, K. , Mitchell, S.C., Zhou, Y., 
Kuo, J., Raitano, A.B., Jakobovits, A., Saffran, D.C., Affar, D.E. (1999). "STEAP: a 
prostate-speciﬁc cell-surface antigen highly expressed in human prostate tumours." Proc. 
Natl. Acad. Sci. USA 96(25): 14523-14528. 
  
Humphrey, P. A., Dehner, L.P., Pfeifer, J.D. (2008). Washington Manual of Surgical 
Pathology Reproductive tract - Prostate, Lippincott Williams & Wilkins. 1st edition. 
  
Jones, G. W. (1993). "Prostate cancer. Magnitude of the problem: American College of 
Surgeons Database and Epidemiologic Study." Cancer 71(3 Suppl): 887-889. 
  
Jones, P. A. and Baylin, S. B. (2002). "The fundamental role of epigenetic events in 
cancer." Nat Rev Genet 3(6): 415–428. 
References 
58 
 
Jones, P. A. and Laird, P.W. (1999). "Cancer epigenetics comes of age." Nat. Genet. 
21(2): 163-167. 
  
Jussi, P. E. and Visakorpi, T. (2001). "Molecular genetics of prostate cancer." Ann Med 
33(2):130-141. 
  
Klatt, E. C. (2006). Robbins and Cotran ATLAS OF PATHOLOGY. The male genital tract. 
S. Elsevier. Second edition. 
  
Kobayashi, H., Nagato, T., Sato, K., Aoki, N., Kimura, S., Murakami, M., Iizuka, H., Azumi, 
M., Kakizaki, H., Tateno, M.,  Celis, E. (2007). "Recognition of prostate and melanoma 
tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T 
lymphocytes in a human leukocyte antigen class II-restricted manner." Cancer Res. 
67(11): 5498-5504. 
 
Koeneman, K. S., Pan, C.X., Jin, J.K., Pyle, J.M. 3rd, Flanigan, R.C., Shankey, T.V., Diaz, 
M.O. (1998). "Telomerase activity, telomere length, and DNA ploidy in prostatic 
intraepithelial neoplasia (PIN)." J Urol 160(4): 1533-1539. 
  
Kohli, M. and Tindall, D.J. (2010). "New developments in the medical management of 
prostate cancer." Mayo Clin Proc 85(1): 77-86. 
  
KoshIji, M., Kageyama, Y., Pete, E.A., Horikawa, I., Barrett, J.C., Huang, L.E. (2004). 
"HIF-1αinduces cell cycle arrest by functionally counteracting Myc." EMBO J 23(9): 1949-
1956. 
  
Kumar, V., Abbas, A.K., Fausto, N. (2005). Pathologic Basis of Disease 7th edition, 
chapter 21: 1047-1056. 
  
Labrie, F., DuPont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.L., Emond, J. 
(1992). "Serum prostate specific antigen as pre-screening test for prostate cancer." J Urol 
147(3 Pt 2): 846–851. 
  
Lagakos, S. W. and Hoth, D.F. (1992). "Surrogate markers in AIDS: where are we? Where 
are we going?" Ann Intern Med 116(7): 599–601. 
  
Laird, P. W. (2005). "Cancer epigenetics." Hum Mol Genet 14 Spec No 1: 65–76. 
References 
59 
 
Li, F. P. (1993). "Molecular epidemiology studies of cancer in families." BR J Cancer 
68(2): 217-219. 
  
Li, L., Li, J., Shen, Z., Liu, W., Chen, Z. (2004). "Clinical significance of six-
transmembrane epithelial antigen of the prostate expressed in prostatic carcinoma." 
Zhonghua Nan Ke Xue 10(5): 351-354. 
  
Liu, M., Peng, Y., Wang, X., Guo, Q., Shen, S., Li, G. (2010). "NGX6 gene mediated by 
promoter methylation as a potential molecular marker in colorectal cancer." BMC Cancer 
10(160): 1-10. 
 
Ludwig JA, W. J. (2005). "Biomarkers in cancer staging, prognosis and treatment 
selection." Nat Rev Cancer 5(11): 845-856. 
  
Madu, C. O. and Lu, Y. (2010). "Novel diagnostic biomarkers for prostate cancer." J 
Cancer 1: 150-177. 
  
Maherali, N., Shridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., Stadtfeld, M., 
Yachechko, R., Tchieu, J., Jaenisch, R., Plath, K., Hochedlinger, K. (2007). "Directly 
reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue 
contribution." Cell Stem Cell 1(1): 55-70. 
 
Maia, C. J., Socorro, S., Schmitt, F., Santos, C.R. (2008). "STEAP1 is over-expressed in 
breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat 
mammary gland." Endocr 34(1-3): 108-116. 
  
Marchand, L. L., Kolonel, L.N., Wilkens, L.R., Myers, B.C., Hirohata, T. (1994). "Animal fat 
consumption and prostate cancer: a prospective study in Hawaii." Epidemiology 5(3): 276-
282. 
  
Matzkin, H., Patel, J.P., Altwein, J.E. Soloway, M.S. (1994). "Stage T1a carcinoma of the 
prostate." Urology 43(1): 11-21. 
  
McConnell, J. D., Roehrborn, C.G, Bautista, O.M. Andriole, G.L. Jr, Dixon, C.M., Kusek, 
J.W., Lepor, H., McVary, K.T., Nyberg, L.M. Jr, Clarke, H.S., Crawford, E.D., Diokno, A., 
Foley, J.P., Foster, H.E., Jacobs, S.C., Kaplan, S.A., Kreder, K.L., Lieber, M.M., Lucia, 
M.S., Miller, G.J., Menon, M., Miliam, D.F., Ramsdell, J.W., Schenkman, N.S., Slawin, 
References 
60 
 
K.M., Smith, J.A. (2003). "The long-term effect of Doxawsin, Finasteride, and combination 
therapy on clinical progression of benign prostatic hyperplasia." N Engl J Med 349(25): 
2387-2398. 
  
McNeal, I. T., Villers, A.A., Redwine, E.A. Freiha, F.S., Stamey, T.A. (1990). "Histologic 
differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of 
the prostate." Cancer 66(6): 1225-1233. 
McNeal, J. E. (1969). "Origin and development of carcinoma in the prostate." Cancer 
23(1): 24-34. 
  
McNeal, J. E. and Bostwick., D.G. (1986). " Intraductal dysplasia: A premalignant lesion of 
the prostate." Hum Pathol 17: 64-71. 
  
Messina, M. J., Persky, V., Setchell, K.D., Barnes, S. (1994). "Soy intake and cancer risk: 
a review of the in vitro and in vivo data." Nutr Cancer 21(2): 113-131. 
  
Mettlin, C., Lee, F., Drago, J., Murphy, G.P. (1991). "The American Cancer Society 
National Prostate Cancer Detection Project. Findings on the detection of early prostate 
cancer in 2425 men." Cancer 67(12): 2949-2958. 
  
Mettlin, C., Littrup, P.J., Kane, R.A., Murphy, G.P., Lee, F., Chesley, A., Badalament, R., 
Mostofi, F.K. (1994). "Relative sensitivity and specificity of serum prostate specific antigen 
(PSA) level compared with agereferenced PSA, PSA density, and PSA change." Cancer. 
74(5): 1615–1620. 
  
Miet, S. M., Neyra, M., Jaques, R., Dubernard, P., Revol, A.A., Marçais, C. (1999). 
"RER(+) phenotype in prostate intra-epithelial neoplasia associated with human prostate-
carcinoma development." Int J Cancer 82(5): 635-639. 
  
Montironi, R., Mazzucchelli, R., Lopez-Beltran, A., Cheng, L., Scarpelli, M. (2007). 
"Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed 
preneoplastic lesions in the prostate." Nat Clin Pract Urol 4(6): 321-332. 
  
Moul, J. W., Sesterhenn, I.A., Connelly, R.R., Douglas, T., Srivastava, S., Mostofi, F.K., 
McLeod, D.G. (1995). "Prostate-specific antigen values at the time of prostate cancer 
diagnosis in African-American men." JAMA 274(16): 1277-1281. 
  
References 
61 
 
Narod, S. A., Dupont, A., Cusan, L., Diamond, P. (1995). "The impact of family history on 
early detection of prostate cancer." Nat Med 1(2): 99-101. 
  
Nelson, W. G., DeMarzo, A.M., Isaccs, W.B (2003). "Prostate cancer." N Engl J Med 349: 
366-381. 
  
Oh, W. K., Hurwitz, M., D'Amico, A.V., Richie, J.P., Kantoff, P.W. (2003). "Neoplasms of 
the Prostate." Cancer Medicine. 6th Edition. Chapter 108. 
  
Ohgami, R. S., Campagna, D.R., McDonald, A., Fleming, M.D. (2006). "The STEAP 
proteins are metalloreductases." Blood 108(4): 1388-1394. 
  
Partin, A. W., Yoo, J., Carter, H.B., Pearson, J.D., Chan, D.W., Epstein, J.I., Walsh, P.C. 
(1993). "The use of prostate specific antigen, clinical stage and Gleason score to predict 
pathological stage in men with localized prostate cancer." J Urol 150(1): 110-114. 
  
Perner, S., Demichelis, F., Beroukhim, R., Schmidt, F.H., Mosquera, J.M., Setlur, S., 
Tchinda, J., Tomlins, S.A., Hofer, M.D., Pienta, K.G., Kuefer, R., Vessella, R., Sun, X.W., 
Meyerson, M., Lee, C., Sellers, W.R., Chinnaiyan, A.M., Rubin, M.A. (2006). 
"TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of 
prostate cancer." Cancer Res 66(17): 8337-8341. 
  
Perner, S., Mosquera, J.M., Demichelis, F., Hofer, M.D., Paris, P.L., Simko, J., Collins, C., 
Bismar, T.A., Chinnaiyan, A.M., De Marzo, A.M., Rubin, M.A. (2007). "TMPRSS2-ERG 
fusion prostate cancer: an early molecular event associated with invasion." Am J Surg 
Pathol 31(6): 882-888. 
  
Pfaffl, M. W. (2001). "A new mathematical model for relative quantification in real-time RT-
PCR." Nucleic Acids Res 29(9): e45. 
  
Pienta, K. J. and Esper, P.S. (1993). "Risk factors for prostate cancer." Ann Intern Med 
118(10): 793-803. 
  
Polascik, T. J., Oesterling, J.E., Partin, A.W. (1999). "Prostate specific antigen. A decade 
of discovery-what we have learned and where we are going." J Urol 162(2): 293-306. 
  
References 
62 
 
Potter, S. R., Epstein, J.I., Partin, A.W. (2000). "Seminal vesicle invasion by prostate 
cancer: prognostic significance and therapeutic implications." Rev Urol 2(3):190-195. 
  
Qian, J., Bostwick, D.G., Takahashi, S., Borell, T.J., Herath, J.F., Lieber, M.M., Jenkins, 
R.B. (1995). "Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma 
detected by fluorescence in situ hybridization." Cancer Res 55(22): 5408-5414. 
  
Ramsey, E. W. (2000). "Benign prostatic hyperylasia: a review." Can J Urol 7(6): 1135-
1143. 
  
Rao, A. R., Motiwala, H.G., Karim, O.M. (2008). "The discovery of prostate-specific 
antigen." BJU Int 101(1): 5-10. 
  
Rhodes, D. R. Sanda, M.G., Otte, A.P. Chinnaiyan, A.M., Rubin, M.A. (2003). "Multiplex 
biomarker approach for determining risk of prostate-specific antigen-defined recurrence of 
prostate cancer." J Natl Cancer Inst 95(9):661-8. 
  
Rolan, P. (1997). "The contribution of clinical pharmacology surrogates and models to 
drug development: a critical appraisal." Br J Clin Pharmacol 44(3): 219–225. 
  
Rubin, M. A., Zhou, M., Dhanasekaran, S.M. Varambally, S., Barrette, T.R., Sanda, M.G., 
Pienta, K.J., Ghosh, D., Chinnaiyan, A.M. (2002). "a-Methylacyl coenzyme A racemase as 
a tissue biomarker for prostate cancer." JAMA 287(13): 1662-1670. 
  
Saitoh, H., Hida, M., Shimbo, T. Nakamura, K., Yamagata, J., Satoh, T. (1984). 
"Metastatic patterns of prostatic cancer: correlation between sites and number of organs 
involved." Cancer 54(12):3078-3084. 
  
Sakr, W. A., Grignon, D.J., Haas, G.P., Heilbrun, L.K., Pontes, J.E., Crissman, J.D. 
(1996). "Age and racial distribution of prostatic intraepithelial neoplasia." Eur Urol 30(2): 
138-144. 
 
Santos C, Socorro S, Maia C. STEAP1 (Six Transmembrane Epithelial Antigene of the 
Prostate 1). Atlas Genet Cytogenet Oncol Haematol. 2010; 14(5):482-484. 
  
Sawyers, C. L. (2008). "The cancer biomarker problem." Nature 452(7187): 548-552. 
  
References 
63 
 
Schröder, F. H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., 
Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L.J., Recker, F., Berenguer, A., 
Määttänen, L., Bangma, C.H., Aus, G., Villers, A., Rebillard, X., Van Der Kwast, T., 
Blijenberg, B.G., Moss, S.M., De Koning, H.J., Auvinen, A. (2009). "Screening and 
prostate-cancer mortality in a randomized European study." N Engl J Med 360(13): 1320–
1328. 
  
Seeley, R. R., Stephens, T.D. and Tate, P. (2004). Anatomy and physiology. 
"Reproductive System”. sixth edition, chapter 28: 1017-1031. 
  
Selley, S., Donovan, J.,  Faulkner, A., Coast, J., Gillatt, D. (1997). "Diagnosis, 
management and screening of early localised prostate cancer." Health Technol Assess 
1(2): 3 - 9. 
 
Sobin, L., Gospodarowicz, M. and Wittekind, C. (2009). TNM Classification of Malignant 
Tumours. Seventy Edition. 
  
Stamey, T. A., Dietrick, D.D., Issa, M.M. (1993). "Large, organ confined, impalpable 
transition zone prostate cancer. Association with metastatic levels of prostate specific 
antigen." J Urol 149(3): 510-515. 
  
Stanford, J. L., Stephenson, R.A., Coyle, L.M., Cerhan, J., Correa, R., Eley, J.W., Gilliand, 
F., Hankey, B., Kolonel, L.N., Kosary, C., Ross, R., Severson, R., West, D. (1999). 
"Prostate Cancer Trends " National Cancer Institute NIH Pub No 99-4543. 
  
Steinberg, D. M., Sauvageot, J., Piantadosi, S., Epstein, J.I.  (1997). "Correlation of the 
prostate needly biopsy and radical prostectomy Gleason grade in academic and 
community setting." Am J Surg Pathol 21(5): 566-576. 
  
Stenman, U. H., Hakama, M., Knekt, P., Aromaa, A., Teppo, L., Leinonen, J. (1994). 
"Serum concentrations of prostate specific antigen and its complex with alpha 1-
antichymotrypsin before diagnosis of prostate cancer." Lancet. 344(8937): 1594–1598. 
   
Suh, E. R., Ha, C.S., Rankin, E.B., Toyota, M., Traber, P.G (2002). "DNA Methylation 
Down-regulates CDX1 Gene Expression in Colorectal Cancer Cell Lines." Journal of 
Biological Chemistry 277(39): 35795-35800. 
 
References 
64 
 
Stransky, N., Vallot, C., Reyal, F., Bernard-Pierrot, I., de Medina, S.G., Segraves, R., de 
Rycke, Y., Elvin, P., Cassidy, A., Spraggon, C., Graham, A., Southgate, J., Asselain, B., 
Allory, Y., Abbou, C.C., Albertson, D.G., Thiery, J.P., Chopin, D.K., Pinkel, D., Radvanyi, 
F. (2006). "Regional copy number-independent deregulation of transcription in cancer." 
Nat Genet 38(12): 1386–1396. 
  
Swinnen, J. V., Roskams, T., Joniau, S., Van Poppel, H., Oyen, R., Baert, L., Heyns, W., 
Verhoeven, G. (2002). "Overexpression of fatty acid synthase is an early and common 
event in the development of prostate cancer." Int J Cancer 98(1): 19-22. 
 
Tamura, T. and Chiba, J. (2009). "STEAP4 regulates focal adhesion kinase activation and 
CpG motifs within STEAP4 promoter region are frequently methylated in Du145, human 
androgen-independent prostate cancer cells." Int J Mol Med 54: 599-604. 
  
Tomlins, S. A., Rhodes, D.R., Perner, S., Dhanasekaran, S.M., Mehra, R., Sun, X.W., 
Varambally, S. Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J.E., Shah, R.B., Pienta, 
K.J., Rubin, M.A., Chinnaiyan, A.M. (2005). "Recurrent fusion of TMPRSS2 and ETS 
transcription factor genes in prostate cancer." Science 310(5748): 644-648. 
  
Tomuleasa, C., Kacsó, G.,  Soriţău, O., Şuşman, S.,  Irimie, A., Virág, P. (2010). "Cellular 
interactions in prostate cancer genesis and dissemination. Looking beyond the obvious." 
Rom J Morphol  Embryol 51(3): 427–435. 
 
Tost, J. (2008). "Epigenetics." Horizon Scientific Press, Norwich, UK. 
  
Tost, J. (2009). DNA Methylation: Methods and Protocols. DNA Methylation: An 
Introduction to the Biology and the Disease-Associated Changes of a Promising 
Biomarker. H. Press. 507. 
 
Urisman, A., Molinaro, R.J., Fischer, N., Plummer, S.J., Casey, G., Klein, E.A., Malathi, 
K., Magi-Galluzzi, C., Tubbs, R.R., Ganem, D., Silverman, R.H., Derisi, J.L. (2006). 
"Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for 
R462Q RNASEL variant." PloS Pathog 2(3): e25. 
 
Vaghjiani, R.J., Talma, S., Murphy, C.L. (2009). "Six-Transmembrane Epithelial Antigen of 
the Prostate (STEAP1 and STEAP2) - Differentially expressed by Murine and Human 
Mesenchymal Stem Cells." Tissue Enginnering 15(00): 1-11. 
References 
65 
 
Valenti, M. T., Dalle Carbonare, L., Donatelli, L., Bertoldo, F., Giovanazzi, B., Caliari, F.,Lo 
Cascio, V. (2008). "STEAP mRNA detection in serum of patients with solid tumours." 
Cancer Letters doi:10.1016/j.canlet.2008.07.037. 
  
Willman, J. H. and Holden, J.A.  (2000). "Immunohistochemical staining for DNA 
topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate." 
Prostate 42(4): 280-286. 
  
Wilt, T. J. (2003). "Prostate Cancer: Epidemiology and Screening." Rev Urol 5 (Suppl6): 
S3-S9. 
  
Wong, Y. C. and Wang, Y.Z. (2000). "Growth factors and epithelial-stromal interactions in 
prostate cancer development." Int Rev Cytol 199: 65-116. 
  
Yasunaga, Y., Shin, M., Fujita, M.Q., Nonomura, N., Miki, T., Okuyama, A.,  Aozasa, K. 
(1998). "Different patterns of p53 mutations in prostatic intraepithelial neoplasia and 
concurrent carcinoma: analysis of microdissected specimens." Lab Invest 78(10): 1275-
1279. 
 
Yip, I., Heber, D., Aronson, W.  (1999). "Nutrition and prostate cancer." Urol Clin North 
Am, 26(2): 403-411. 
 
Young, B., Lowe, J.S., Stevens, A., et al. (2007). Wheater's Functional Histology - A text 
and colour atlas. Male reproductive system Elsevier. 5th edition  
Appendix 
 
66 
 
APPENDIX  
Figure A1: Location of region rich in CpG islands, in STEAP1 gene. 
 
In order to ensure that cell lines culture was mycoplasm-free PCR reactions were carried 
out. 
 
 
 
 
 
 
 
 
Figure A2: Running of the amplified nested-PCR products, in agarose gel. A – First PCR, B – 
Second PCR. In both, 1 – LNCaP, 2 – PNT1A, 3 –PNT2 and 4 negative control. 
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TTTTTATAAGAAGTGTAGAAATAAAATTGTTAAAGTTTAATTATAAAATAAAAATATTTGGGGTTTGATTTTA
AATGTTTTAATTAGAAAAGGAAAAGTAGTTTTAAGTGTAGTTTGTTATATAGTTATATTTATATGAATATATA
TTATTATGTTAATATAATAATAATTTTTTGTTTTTTTTATATGGAAAATAGATTGTGAAAAATAGAATGATTT
TTGTTTTATTAAATGTTAAATAATAAAAGTATATCGTTTTGTTTGATTATTTAAGATTTATGATTATTTTTAA
AATTTAATAATGTTTAGTTAAAAAGTTTTAATTTTTTGTAGTTTGTGTTATATATATAAAGATTATATAGATT
TTTTTTTTAAAATTTTTAAATTATTTTTTAGTTTTATTAGAAATAATAGGTGTAAGATTTTATTTTTATTATA
AGGTGTTAGTTTACGGTAATTTAAGTTTTAAAGGGTTTTAAATTAATTTAAGGAAAGTTAGTGATTATAGAAA
ATATTTATATTAAAATATGTTTTGTTAAACGGATGTTTGAAGGCGGTATGTTAGTTAAGAGTTATTATTATTT
TTTAATTTTAAGTATTTAGGGATATAAATATTGCGGAAGGTCGTAGGGTTTTTTGTTTAGGAAAATTAGAGAA
TTTTGTTTATTTGTTTATTTGTTGATTTTTTTTTTATTATTGTTTTATGATTTTGTTAAATTTTTTTTTGCGA
GAAATATTTAAGAATGATTAATAAAAAAAAATAATAATAATTAAAAAAAAAAAAGTAAAAAAAAAAAAAAAAA
AAAAAAAAAAATATGAATAGTTTTCGGTGTTTTAGTAGTGAATAAAAAATAATTATGGAAAATGTGGTTGCGC
GTTTATTTTTTTTTGTGTTTTTTATTTAGTTTAGTTTTGAGAATGTTGTATATTAAATTTTTAGAATTTTGTA
ATTTATGTTTTAGATTTTATTTTGAGGTTGGTTTTAACGGAGAGAAGTAAATTTTTTGTTTAAGTTGTTTTTT
TTTAAAATTTTGGAATATTAATAGTTAATTTTATTTTAGGTTTGGAATATTTTATTGAGTTAGGATATGGGAA
GTTGTATTTAAAAGTTAAGGTAAGGAAGGGAGGGACGGAGTAAATATGGGGTTTAAGGGTTTTTTTTTCGGTT
GGGGAGTAGGGTTTGTGCGATTAAAGGTATATAATTTGAATAATTTAGGGAGTAAGTTATTTTTAGAAATTTA
GTTTCGGATTTTTTAAATTGTTAATTATAGTTATTTTAGGATCGGTTGTTAGGTTTTAAATAAGGTGGTTGGG
CGCGGTGGTTTACGTTTGTAATTTTAGTATTTTGGGAGGTCGAGGCGGGTGGATTACGAGGTTAGGAATTTAG
GATTAGTTTGGTTAAGATGGTGAAATTTTCGTTTTTGTTGAAAATATAAAAATTAGTCGGGTATAGTGGTAGG
CGTTTGTAATTTTAGTTATTCGGGAGGTTGAGGTAGGAGAATCGTTTGAATTCGGGGTTGGAGGTTGTAGTGA
GTTAAGATCGCGTTATCGTATTTTAGTTTGGGTAATAGATTGAGATTTCGTTTTAAAAAAAATAAAAATAAAA
TAAAAATAAATAAGTTAACGTGTGGGAGGGTTTGTAAGTTTTAAACGGTTTATTTTAAAGTGTGATTTGGGAA
TGTTTTTATATTTTATGGGAATTTGTTATAAATGAGAATTTTAGATTTTATTTTAGATATATTGAATCGGAAA
TTGTGGGCGGATAGTTTAATAATCGGTGTTTTAATAAGTTTTCGGGTAATTTTATATACGTTAAAGTTTGAGA
ATTATTGTTTTAGAGAAATGTATAAACGTTTTTTAGTGGAGATTAAATAAAAGGCGAGGGGTTGGAGGGCGCG
AAACGGATTTTAGGTGTAGGGTAGACGGTATTTGAGAGGAAATTGGGAGAGGTCGGAGTGCGATTTGGGGAGT
TTTAGTTTTTAAGGACGTTTCGGAATTTTGCGGACGCGGGGCGTTAGTAGGTGGCGTTGGACGCGTAACGGAT
AAGGAGGCGGGGTTTGTAGTTGGTTTGGAGGTTTCGCGTTTTGGAGGTTTAGGCGTCGCGTGGGGTTCGTATT
TTTGGGTAGTAGCGGTAGTCGAGATTTACGGTTAAGTTAAGGCGAAGAGTGGGTGAGTTTTTTGAATCGTTTT
TATTGGTCGTTTGTTTTTCGAGTTCGTTCGCGTGTTTTTGTAAGGTTGGGCGTTCGTTTTTAGTTTTGGGAGG
GGTGTAGCGGGTCGTAAGTTTTTTCGTGATTTGGATAGCGGTTTTTTTGGGCGAGCGTTGTTTAATTTTTCGT
TTATGCGCGGTTTTGGGGCGCGTTGTTTTTTAGTTTAGTTGGGTTGTGGTCGGGTCGGGGGTTGGGGAGAGTT
AGGGATTTATAGGAAGTTTTTTCGTTAGGGGTTTAAGGTTGTGGTAGATTATTAAGTTTGTGTTTAGGTTGGA
TTTTGATGGTAAGTTTTTTAACGTGGTAAAGTTGTTAGAGTTTGTTGTGTATTGACGAATGATTGGTGTATAG
TATTTAAAATCGTGTTATTTTTCGTTTTCGGGTTTTTTGGTAATAGAGGTTTTTATTTTTAGTTTTTAGAATA
TTGGTTTTATTTTTTTAGGATTTGGGTGGGGTTTAGGTTTTTTTTAAAATAGTTAATTAAGGTTTTAAATATG
TAATTTTGGTTAAATTTATTGGAAGGTGTTTGTAGATATAAATTTTTTGTATATTTTTAAATTTTTTATTTTG
TTATTTTTGTAAAATATATTTTTTTTTATATTTTGACGTGTAATAAAAGGTTATTTATTTAATATGAATGTTA
AGTATAGAGGGAAAGTAATGTTTAAAAATAGTTTAGTGAAAAAAAAAAATAAAAAATTCGATTTTATTTAGTT
AAATGTAAAATAAGTGTGTATTTGAAAGTATAAAAGGTTGGAAATGTAATGTAATTTATAGTGTATTTTAGGT
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ATTGGGTTTTTTTATATTTTTAATTGCGGGATATAAATATGAGTAAGTTGGGTTGTGTTAATATTTAGGAATA
TTAGGGTAGTTATTTTGGTATAGTAAAATAGTAGTCGTATTAGAAATATGTTTTATTTTTTTTAAAAGGGGGT
GAAAGAGAATTTTGGGTCGAATTTTGGAGTTTTTAATATTTTAATATTAGGTTGTTTTTTGTTATTTTTTTTT
TTATGAAAAGATTTTATTGTAGAATTTAAATTTTATTTTGGTTAATGTTTGATGGAAATTAATAAATTTATTT
GATTTATAGTTTATTTTTTTGGTTTATGGGTATAGAGTTGATTGTGGGTTATATAGTTAATAAGTTTTTTTAT
TGTTATGGGTTTTTTTTTGGTTTTGTTTTTGAGTGTGGTTTTTTTATTATGTAGATAAATGGTTGGGTAATTT
TTTAGGGTTATTTTGGTTTTTTATTTAGATTTCGTTTGTAGTGGTTATTAGTTAGTAAATATTGTTAATTTGT
TAGTTATTTTAGGATTGGGTTTAGAAGATAGCGTTGAGTTTTTTTTTTTATTTTTTTTTTTATGTTATTATTT
GTTTGTAAAATTTTATTTTTTTTTAGGATATATCGTTTTATTATGTAGTTGAAATGTTTGTTTTTTTTTTTAG
ATTTTAAGGTTTTTTAGAGTAGAGGTTTTATTTTATTTAATTTTGTATTTTTTTTGTTTTATATTGTTGTTTA
TAATATAGTTAATGAATTTATATTGAATAAATGTAGGTGGATTTGTTAGTATTTTTACGATATTGTAATTTTT
AAAGTTAAAAGATTTTTTAAATATAGTGAATTATTTTTTATATTTGATTATAGTAGGTGATATTTTTATTTTT
AGTATTTTTTTTTTTTATTTTATAAATTATTATGTTGGTGATATGGTTTGGAGTTGTGTTTTTTTTTTAGATT
TTATGTTGAAATGTAATTTTTAGTGAGGGAGTTGGGGTTTGGTGGGAGGTGATTGGATTATGGGAGTAGTTTT
TTATGGTTTAATATTATTTTTTTTTGGTGTTGTTGTTACGTTAGTGTAGGGGTATTTAATTTCGTGGTCGTAG
ATTGGTATTAGTTAGTGTTTTTTTAGGAATTGGGTTGTATAGTAGGAGGGGAGTGGTAGGTTAGCGAGTATTA
TTGTTTGAGTTTTATTTTTTGTTAGATGAATAGTGGTATTAGATTTTTTTAAGTGTATGAATTTTATTGTAAA
TTGTATATGTAAGGGATTTAGGTTGTGTGTTTTTTATGAGAATTTAATTATTGTTTGATGATTTGAGGTGGAA
TAGTTTTATTTTAAAATTTTATTTTTTTTTTTTTATTTGGAAAAATTGTTTTTTACGAAATTAGTTTTTGGTG
TTAAAAAGGTTGGGGATTATTGCGATAATGTAAGACGTTTGTTTTTATTTTATTTTTCGTTATGATTATAAGT
TTTTTGAGTTTTTTTTAGAAGTAGATGTTGTTATGTTTTTTTTATAGTTTATGGAATTATGAGTTAATTAAAT
TTTTTTTTTTTATAATAATTATTTAGTTTTAGGTATTTTTTTATAGTAGTGCGAGAATAGCGTAATATAGTTG
GTTAAGTTATTAAATGATTTGGAATAATGTTTTTTAAGGAGATAGAGTGTTATTTTTTTTAGAGTAGGTATGA
GTGTTATTTTTATTTTTTTTTTTTAATGTTGGTTATAGAGTTGGGTTTATAAATATTTGATGATTGGTATATG
TTTTATTTAGAATTTTTTTATATGTTAGTGGTGAATATTTAAATTATATTAATTTAAATTAAAAAAAAAGGGA
ATGTGTTGATTGTTTAATTGAAAAATTTAGGATTTAGTTTTAGGGGTTTTAAATATTGAAATATGTCGTTAGG
ATTTTTTTGTGTTTTTTTTTGTTTTTTGTTTTGTTTTCGTGTTGGTTTTTTTTTTTTTTAATGAAAATATGTT
TTTTTTTAGAGTATGGAGAAAAAAGTATGGTAGGTTTATATTGTGTTATTTTAATAAAATGTTAAAGATATTT
TATTTTTTTTTTTTATTTTTATATATAAATATTAGAGAATGATTAGGTTTAAGTAGGGTTTTGTGTTATCGTT
AAGTTAATTAATGGGAAAATAGGAAATTGTTTAGGTTTGAGTTATATATTTATTTTTGTGATTAGGGAATGAG
CGTTATTATTTTATATAATTTTTTAAAATTATATTGGAGGGAGGAAGGGTATTTTTTTAAATGGAGGAAATGT
TTTAAATTAGAAAAGAATGTGGGTAAATTAAAATAATAGATATTTTTATTATGAATGTTTTGTAATTTTGAAA
TAGATAATATTTGGAAAATATTTTAAGAGTATTTTAATAAAGTAAATGTTGGTATATGTAAAAGTAATTCGTT
ATTTTTTGTTATAGTTAAATTTTTAAAATTTGGAGAATGTTTTAAGAATAGTTATGTTTTTTTATGATAGGAT
ATATTTTGAGAAATTTATTGTAAGGCGGGATTTTATTGTTGAGGAAATATTATAGAGTGTATTTATATAAATT
TAGATGGTATAGTTTTTTATATATTTAGGTTAGATGGTATAGTTTATTGTTTTTAGGTTATTAATTTGTATAG
TATGTTATTGTGTTGAATATTGTGGGTAGTTGAAATATAATAGTAAGTATTTGTGTATTTGAATATAGAAAAG
GTATAGTAAATATATATATATCGTATAAAAGATAAAAAATTGTATATTTGTATAGGACGTTTATTATGAATAG
AATTTGTAGAATTGGAAGTTGTTTTGGGTGAGTTAGTGAGTGAGTAGTGAGTGAATGTAAAGGTTTGGGATAT
TATTGTATAGTATTATAGATTTTATAAATATTGTATATTAAGGTTATTTTATATTTATTGAAAAATTTTTTTT
TTTAATAATAAATTAATTTTAGTTTATTGTAATTTTATTTTATTAATTTATTGTTTTTATTTTTTTGTAATAA
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TATTTAGTTTAAAATATAGTTATATTGTATAGTTATATAAAATATTTTGTTTATGTATTTATTTTTTAAGTTT
TTTTTTTATTTTTAATTTTTTTTTTTTTTTTAGATTTTTTTGTTGAAATTAAGATATAAATATATATATTAGT
TTAGGTTTATTTAGGGTTAGGATTATTAGTATTATTGTTTTTTATTTTTATATTTTGTTTTATTGGAAGGTTT
TTAAGGGTAGTAATAGGTATGGAGTTGTTATTTTTTATGATAATAATGTTTTTTTTTGGAAGATTTTTTGAAG
GATTTGTTTAGGGTTGTTTATAGTTAGTTTTTTTTTTGTAAGTAGAAGGAGTATATTTTATAATAATAATAAA
AAGTATAGTATTGTAAATATTAGGTAATAGGAATTTTTTTGTTTTATTATATTTTTATGGGATTATTGTTATA
TATGTAGTTAGTCGTTGATTAAAGTGTTATGTGATATATTATTGTATTTTAAATTATTTTTGGAAATAGTTTT
TTATTTAAAAAAGTATTATACGTGGTTTAAAATTTAGAAATATTTGGGATATTTTTTGTTAATTAAATTGTTG
TATATTTAATTTGTTTTTTTTATTGAATTTTATAAAGTGTAAATTGAAGATGTGTTTTTTTGGAAATAAATTT
AGAATTAATAAAAATAATGAATAGTATTGTGATATATGTTTTTTTTTTTTAAAAAATGTTATATTAATTTTGG
ATGAGGATTTGTGAGTTTGTTAAGGAAAAGATTTTTTTATTAAGTGAGAAATTTGAAAAGTTGTTTTTTATAG
GGTTGATTAGAAGATTGGGTATATTATTAATTCGGTATAATTTATTATTTTTATTGGAAATATATTAGTAATT
TATATTTTTTAAATAAGTATTAATTTTTTATTTTAAAAGAAAAATGGTATTTTGAAAATATTGTTTTAGATTT
TAGTGTTAATTTTAAAATTTTGTTAAATATAAATTTTATATTAGTTATTTTTAGTTTTTATTGATGATATTAT
TATTTTTAATATAATATATTTTTAATTATATTTGTTATTGAAAGGAGTTGGTTTTTTTTTAGATGGAAATTTG
AAATTAAATTTTTTTTAAGTAAAAGGTAATATTTGATTTTTTGTAATGTATATAGGTATTTGGGTTATTTATT
GAATAAATAAGTAGATAAAGAAGAGTAGTTATTGTTGATAAGAGGGTATTGGTTTGAAATTTATAGATTATAA
TATGAAGTTAAATGTATAAATTAGTTATTATTTTTATTTTTATTGTATTTTATTTGTTATTTTAGTTTTTAAG
TAAGTAAATTTTTTATATTGTTATATTAAATATTTATATTATAAGTAGAATGGATATGAAAGTAATTATTTTT
ATTTTTATAGGTGGTTGAAGTTATATTATTTTATAGAATTAATGGAAAGTAGAAAAGATATTATAAATTAAGA
AGAATTTTGGAAAATGAAGTTTAGGAGAAATTTAGAAGAAGACGATTATTTG 
Figure A3: Bissulfite modification STEAP1 gene sequence and location of the primers for 
methylation. 
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STEAP1B         CATGGGAACTTGTTAGAAATGAGAATCTCAGACCTCATCCCAGACATACTGAACCGGAAA 60 
STEAP1          CATGGGAACTTGTTACAAATGAGAATCTCAGACCCCATCCCAGACATACTGAACCGGAAA 60 
                *************** ****************** ************************* 
 
STEAP1B         CTGTGGGTGGACAGCCCAACAATCGGTGTTTTAATATGCCCCCGGGTAATCTTATACACG 120 
STEAP1          CTGTGGGCGGACAGCCCAACAATCGGTGTTTTAATAAGCCCCCGGGTAATCTTATACACG 120 
                ******* **************************** *********************** 
 
STEAP1B         CTGAAGTCTGAGAACCACTGCTCTAGAGAAATGCACAAACGTTCCTTAGTGGAGATTAAA 180 
STEAP1          CTAAAGTCTGAGAACCACTGCTCTAGAGAAATGCACAAACGTTCCTTAGTGGAGATTAAA 180 
                ** ********************************************************* 
 
 
STEAP1B         CAAAAGGCGAGGGGTTGGAGGGCGCGAAACGGACCTCAAGGGCAGGGCAGACGGCATTTG 240 
STEAP1          CAAAAGGCGAGGGGTTGGAGGGCGCGAAACGGACCTCAGGTGCAGGGCAGACGGCATTTG 240 
                ************************************** * ******************* 
 
STEAP1B         AGAGGAAACTGGGAGAGGCCGGAGTGCGACTTGGGGAGTCTTAGCCTCCAAGGACGTTCC 300 
STEAP1          AGAGGAAACTGGGAGAGGCCGGAGTGCGACTTGGGGAGTCTTAGCCTCCAAGGACGTTCC 300 
                ************************************************************ 
 
STEAP1B          CGAACCCTGCGGACGCGGGGCGCCAGCAGGTGGCGCTGGACGCGCAACTGACAAGGAGGC 360 
STEAP1           GGAACCCTGCGGACGCGGGGCGCCAGCAGGTGGCGCTGGACGCGCAACGGACAAGGAGGC 360 
                 *********************************************** *********** 
 
STEAP1B         GGGGCCTGCAGCAGGCTTGGAGGCTTCGCGCTCTGGAGGCTCAGGCGCCGCGTGGGGCCG 420 
STEAP1          GGGGCCTGCAGCTGGCTTGGAGGCTCCGCGCTCTGGAGGCTCAGGCGCCGCGTGGGGCCC 420 
                ************ ************ *********************************  
 
STEAP1B         GCACCTCCCGGCAGCAGCGGCAGCTGAGACTCACGGTCAAGCTACGGCGAGGAGTGGGTG 480 
STEAP1          GCACCTCTGGGCAGCAGCGGCAGCCGAGACTCACGGTCAAGCTAAGGCGAAGAGTGGGTG 480 
                *******  *************** ******************* ***** ********* 
 
STEAP1B         AGTCCCTTGAATCGTTCTCACTGGCCGTTTGCTCCTCGAGTCCGCCTGCGTGTCCCTGCA 540 
STEAP1          AGTCCCTTGAATCGTTCTCACTGGCCGTTTGCTCCTCGAGTCCGCCCGCGTGTCCCTGCA 540 
                ********************************************** ************* 
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STEAP1B         AGGCTGGGCGCCCGCTCCCAGTCTTGGGAGGGGTGTAGCGGGTCGCAAGCCTTCTCGTGA 600 
STEAP1          AGGCTGGGCGCCCGCTCCCAGTCTTGGGAGGGGTGTAGCGGGTCGCAAGCCTTCTCGTGA 600 
                ************************************************************ 
 
STEAP1B         CCTGGACGGCGGCCCTCCTGGGCGAGCGGTGCTCAATTCTTCGCTTATGCGCGGCTCTGG 660 
STEAP1           CCTGGACAGCGGCCCTCCTGGGCGAGCGCTGCTCAATTCTCCGCTTATGCGCGGCTCTGG 660 
                ******* ******************** *********** ******************* 
 
STEAP1B         GGCGCCCTGTCTTCCAGCCCAGCTGGGTTGTGGCCGGGCCGGGGGCTGGGGGGAGCCAGG 720 
STEAP1          GGCGCGCTGCCTTCCAGCCCAGCTGGGTTGTGGCCGGGCCGGGGGTTGGGGAGAGCCAGG 720 
                ***** *** *********************************** ***** ******** 
 
STEAP1B         GACTCAGAGGAAGCCTTTTCGCTAGGGGCTTAAGGTTGTGGTAGATTATTAAGTTTGTGC 780 
STEAP1          GACTCACAGGAAGCCTTTTCGCTAGGGGCTTAAGGTTGTGGTAGATTATTAAGTTTGTGC 780 
                ****** ***************************************************** 
 
STEAP1B         TCAGGTTGGATTTTGATGGCAAGTTTTTTAACGTGGCAAAGTCGCCAGAGTTTGCTGTGC 840 
STEAP1          TCAGGTTGGATTTTGATGGCAAGTTTTTTAACGTGGCAAAGTTGCCAGAGTTTGCTGTGC 840 
                ****************************************** ***************** 
 
STEAP1B         ATTGACGAATGACTGGTGCACAGTACTTAAAATCGTGCTACTTCTCGTCTTCGGGTTTCC 900 
STEAP1          ATTGACGAATGACTGGTGCACAGTACTTAAAATCGTGCTACTTCTCGTCTTCGGGTTTCC 900 
                ************************************************************ 
 
Figure A4: Alignment of STEAP1 and STEAP1B sequences (promoter, first exon and first intron). Regions with high homology are depicted with an 
asterisk. CpG islands are highlighted with yellow colour.  
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With TMAs construction, we observed that the block is practically complete, with their 
proper holes filled with the appropriate tissue. It is necessary to take in consideration that 
this image corresponds to the block after alignment and following creation of cutting slides 
that justify an eventual complete lack of tissue in some holes (Figure A5). 
 
 
 
 
 
 
 
 
Figure A5: A – Image corresponding to a TMA block containing prostate cancer tissue, B – back 
TMA block itself appropriately subtitled. C – Image corresponding to a TMA block containing BPH, 
D – back TMA block itself appropriately subtitled. 
 
In figure A6 was depicted the fragments from the corresponding block and it is clear the 
existence of all fragments after the immunohistochemistry, thereby infer the validation 
technique of “TMA”. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A6: A - Slide corresponding to the block 7 above, suitably labeled (STEAP1 antibody), B – 
Slide stained with hematoxylin. C – Slide corresponding to the block 11 shown above, stained with 
hematoxylin, D – Slide suitably labeled (antibody STEAP1). 
 
 
In figures A7 and A8, we can view a representation of a single fragment that allows a 
complete marking of the antibody used, which shows again the effectiveness of this 
technique. 
 
A B C D 
A B C D 
A 
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Figure A7: A – Image representative of a single fragment observed by conventional microscope 
with a magnification 4x, stained with haematoxylin in prostatic tumor tissue; B – Image 
representative of a single fragment observed by convencional microscope with a magnification 4x, 
corresponding to marking the antibody STEAP1 in prostate tumor tissue. 
 
 
 
 
 
 
 
 
 
Figure A8: A – Image representative of a single fragment observed by conventional microscope 
with a magnification 4x, stained with haematoxylin, corresponding to a BPH; B – Image 
representative of a single fragment observed by convencional microscope with a magnification 4x, 
corresponding to marking STEAP 1 antibody, a tissue BPH. 
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Table A1: Patient characteristics according to the present pathologies. 
Patient 
Number 
Age 
Histologic 
diagnosis 
Total-
PSA 
Free-
PSA 
Gleason TNM 
Bone 
metastasis 
H09/1577 62 Adenocarcinoma 
7,43  
μg/L 
11,40% 7 (3+4) 
pT2cNxMx 
R0 
 
H09/12198 59 
Adenocarcinoma 
and ANT 
11,67 
μg/L 
11,30% 7(4+3) pT2cN0Mx No 
H09/947 64 Adenocarcinoma 6,94 μg/L 8,40% 7 (3+4) pT2c  
H11/1568 61 
Adenocarcinoma 
and ANT 
6 μg/L  7 (3+4) pT2aNxMx No 
H11/2741 58 
Adenocarcinoma 
and ANT 
  6 (3+3) pT2NxMx  
H10/14473 68 
Adenocarcinoma 
and ANT 
10,33 
μg/L 
 7 (3+4) pT2aNxMx No 
H11/6193 64 
Adenocarcinoma 
and ANT 
6,92 μg/L  7 (3+4) pT3a  
H10/19013 64 
Adenocarcinoma 
and ANT 
6,28 μg/L  7,60% 10 (5+5) pT3aN0Mx No 
H10/22274 62 
Adenocarcinoma 
and ANT 
3,91 μg/L  15,30% 6 (3+3) 
pT2cNxMx 
R0 
 
H10/17824 62 
Adenocarcinoma 
and ANT 
5,10 μg/L 17,80% 6 (3+3)  No 
H10/21981 62 
Adenocarcinoma 
and ANT 
  7 (4+3) 
pT3aNxMx 
R0 
No 
H10/18249 62 
Adenocarcinoma 
and ANT 
9,07  
μg/L 
14,40% 6 (3+3) 
pT2cNxMx 
R0 
No 
H10/15893 62 
Adenocarcinoma 
and ANT 
  7 (4+3)  No 
H11/2441 60 
Adenocarcinoma 
and ANT 
4,77 μg/L 10,10% 6 (3+3)   
H10/19971 54 
Adenocarcinoma 
and ANT 
3,73 μg/L 22% 7 (3+4)  No 
H11/53 64 
Adenocarcinoma 
and ANT 
  7 (4+3)   
H10/23106 63 
Adenocarcinoma 
and ANT 
6,20 μg/L 6,60% 6 (3+3) pT2a  
H10/14363 63 Adenocarcinoma 4,36 μg/L   7 (3+4) pT3a No 
H10/20715 49 
Adenocarcinoma 
and ANT 
  7 (3+4) pT3aN0Mx  
H10/18633  Adenocarcinoma   7 (3+4) pT2c  
H10/23770 70 
Adenocarcinoma 
and ANT 
  7 (4+3) pT2cNxMx  
H10/19919 70 
Adenocarcinoma 
and PIN 
7,98 μg/L 15,40% 6 (3+3)   
H10/17651 70 Adenocarcinoma 9,90 μg/L 7,90% 8 (4+4) 
pT3aN0Mx 
R0  
 
H11/8473 64 Adenocarcinoma   7 (3+4) pT2 c  
H10/16728 68 Adenocarcinoma   7 (3+4) pT2cN0Mx  
H11/7107 56 
Adenocarcinoma 
and ANT 
8,92 μg/L 24,50% 6 (3+3) pT2cNxMx  
H10/11794 65 Adenocarcinoma 7,15 μg/L 3,90% 7 (3+4)   
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H11/486 67 
Adenocarcinoma 
and ANT 
  6 (3+3)  No 
H10/19716 62 
Adenocarcinoma 
and ANT 
  9 (5+4) pT3a N0  No 
H10/21199 53 
Adenocarcinoma, 
ANT and PIN 
7,14 μg/L  7 (4+3)   
H10/13949 66 
Adenocarcinoma, 
ANT and PIN 
5,9 μg/L 20,20% 7 (3+4)   
H10/16852 59 
Adenocarcinoma 
and ANT 
9,22 μg/L 10,40% 7 (3+4)  No 
H11/4956 41 
Adenocarcinoma, 
ANT and PIN 
5,75 μg/L  7 (3+4) pT2cNxMx No 
H10/21008 71 
Adenocarcinoma 
and ANT 
  7 (3+4)   
H10/7627 54 
Adenocarcinoma, 
ANT and PIN 
  7 (4+3)   
H10/21764 55 
Adenocarcinoma 
and ANT 
  6 (3+3)   
H10/5206 79 Adenocarcinoma 
77,91 
μg/L 
 9 (4+5)  Yes 
H10/6746 59 
Adenocarcinoma, 
ANT and PIN 
  7 (3+4) 
pT2cNxMx 
R0 
 
H10/18197 83 Adenocarcinoma 8,13 μg/L 20,40% 8 (4+4)   
H10/17648 48 
Adenocarcinoma 
and ANT 
  7 (3+4) 
pT2cNxMx 
R0 
 
H10/11096 71 
Adenocarcinoma 
and ANT 
  7 (3+4) pT3aNxMx  
H10/11488 61 
Adenocarcinoma 
and ANT 
  5 (2+3)  No 
H10/14361 72 
Adenocarcinoma 
and ANT 
7,69 μg/L 15,10% 7 (3+4) pT2c No 
H10/3408 64 Adenocarcinoma   7 (4+3) pT2c No Mx  
H10/7559 77 Adenocarcinoma 3,65 μg/L 24,10% 6 (3+3)   
H10/5833 56 
Adenocarcinoma, 
ANT and PIN 
9,51 μg/L 7,80% 7 (4+3) pT2cNxMx  
H10/6833 65 
Adenocarcinoma 
and ANT 
  7 (3+4) pT2bNoMx  
H10/4085 70 Adenocarcinoma 6,39 μg/L 4,10% 7 (4+3)   
H10/7179 62 Adenocarcinoma   7 (3+4) pT2cNxMx  
H10/16784 65 
Adenocarcinoma 
and ANT 
3,24 μg/L 8,30% 7 (4+3)  No 
H10/12719 68 Adenocarcinoma 7,88 μg/L 8,70% 7 (4+3)  No 
H10/8642 69 Adenocarcinoma 3,84 μg/L 10,90% 9 (4+5)  Yes 
H10/11642 67 
Adenocarcinoma 
and ANT 
  7 (4+3) pT3aN0MX  
H10/22762 65 Adenocarcinoma 
12,13 
μg/L 
 7 (3+4)  No 
H10/13366 56 
Adenocarcinoma 
and ANT 
  7 (3+4) pT2bNxMx No 
H10/4207 60 Adenocarcinoma   7 (3+4)  No 
H10/19844 69 Adenocarcinoma   6 (3+3)   
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H10/4331 65 Adenocarcinoma 6,24 μg/L  11,20% 6 (3+3)  No 
H10/16449 68 
Adenocarcinoma, 
ANT and BPH 
11,97 
μg/L  
 6 (3+3)   
H10/12437 54 Adenocarcinoma 4,79 μg/L 11,90% 9 (4+5)  No 
H10/18562 70 
Adenocarcinoma 
and ANT 
  7 (3+4) pT2c  
H10/9687 67 
Adenocarcinoma, 
ANT and BPH 
3,27 μg/L 7,30% 6 (3+3)   
H10/17709 59 
Adenocarcinoma 
and ANT 
3,96 μg/L    No 
H10/8223 53 Adenocarcinoma    pT2c  
H10/9675 74 BPH      
H10/9517 85 BPH 2,96 μg/L 16,90%    
H10/9483 77 BPH 1,29 μg/L     
H10/17115 77 BPH 3,24 μg/L 22,50%    
H10/15289 72 BPH 3,06 μg/L 11,10%    
H10/16086 75 BPH 
10,94 
μg/L  
15,50%    
H10/11458 73 BPH 
11,57 
μg/L 
    
H10/16285 75 BPH 
3,277 
μg/L 
17,70%    
H10/16287 61 BPH 2,22 μg/L     
H10/11786 71 BPH      
H10/24105 59 BPH 
14,80 
μg/L 
    
H10/23010 77 BPH 0,17 μg/L 47,10%    
H10/19403 72 BPH 7,37 μg/L 39,30%    
H10/13365 73 BPH 
1,26  
μg/L 
    
H10/16479 80 BPH 5,65 μg/L 28,80%    
H10/11573 73 BPH 3,62 μg/L 19,10%   No 
H10/12982 61 BPH 
15,40 
μg/L 
17,40%    
H10/17503 73 BPH 
11,31  
μg/L 
    
H10/22495 87 BPH 
11, 34 
μg/L 
    
H10/19842 47 BPH 1,46 μg/L     
H10/11611 63 BPH 2,05 μg/L     
H10/10291 78 BPH 1,29 μg/L     
H10/16409 72 BPH 1,92 μg/L     
H10/11017 64 BPH 1,20 μg/L     
H10/15029 71 BPH 0,94 μg/L     
H10/13972 51 BPH      
H10/21700 66 BPH 3,01 μg/L 18,60%    
H10/19151 56 BPH 0,68 μg/L     
H10/17620 51 BPH 0,52 μg/L     
H10/23383 80 BPH 3,89 μg/L 21,10%    
H10/12196 76 BPH 
5,50  
μg/L 
24,90%    
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H10/19118 41 BPH      
H10/24042 88 BPH 0,72 μg/L     
H10/19628 56 BPH 3,38 μg/L 10,40%    
H10/10296 78 BPH      
H10/17156 72 BPH 0,88 μg/L 20,50%    
H10/17095 77 BPH 1,97 μg/L     
H10/17647 61 BPH 0,40 μg/L     
H10/17097 71 BPH 2,97 μg/L 16,80%    
 
